# **REVIEW**

**Open Access** 

# Postoperative amblyopia in children with congenital cataracts: a systematic review and meta-analysis

Ailifeire Hailaiti<sup>1</sup>, Xiaoning Yu<sup>1</sup>, Ke Yao<sup>1</sup> and Xingchao Shentu<sup>1\*</sup>

# Abstract

This systematic review and meta-analysis aimed to estimate the prevalence of amblyopia following congenital cataract surgery in children and evaluate key prognostic factors, including age at intervention, cataract phenotype, and follow-up duration. We systematically searched PubMed, EMBASE, and the Cochrane Library for studies published between January 1, 1981, and March 1, 2023. We included clinical trials, case series, and observational studies to analyze surgical timing, visual outcomes, and complications. Among 28 studies (2,167 patients, 3,371 eyes), the pooled amblyopia prevalence was 62% (95% CI: 0.55–0.69,  $I^2 = 91.7\%$ ). Early surgery ( $\leq 8$  weeks for unilateral,  $\leq 12$  weeks for bilateral cases) significantly reduced amblyopia risk (P < 0.001) but increased complications, notably glaucoma (26% vs. 6%, P = 0.001). In contrast, intraocular lens (IOL) implantation timing had no significant effect on visual outcomes (P = 0.096). Unilateral partial obstruction conferred a higher amblyopia prevalence than bilateral complete obstruction (68% vs. 36%, P = 0.003), and prolong amblyopia therapy beyond 6 years of age showed limited efficacy. These findings highlight the critical role of timely surgery in optimizing visual recovery, despite its association with complications. Early IOL implantation demonstrated no significant clinical benefits, and the therapeutic window for amblyopia rehabilitation in congenital cataracts is narrower than in other forms.

Keywords Congenital Cataract, Intraocular lens implantation, Amblyopia, Visual acuity, Postoperative complications

# Introduction

Congenital cataracts are a leading cause of treatable childhood blindness worldwide, with a global prevalence of 1-15 per 10,000 children [1]. Characterized by lens opacity that induces deprivation amblyopia and irreversible visual impairment if untreated [2–4]. Usually present at birth or within the first months of life, affecting one or both eyes [5].

\*Correspondence: Xingchao Shentu stxc@zju.edu.cn

<sup>1</sup> Zhejiang University, Eye Center of Second Affiliated Hospital, School of Medicine, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou 310009, China Early intervention ( $\leq 6$  weeks for unilateral,  $\leq 8$  weeks for bilateral) is widely recommended to optimize visual development [6–8]. However, conflicting evidence exists regarding the risks of early surgery, particularly the elevated incidence of aphakic glaucoma and other complications [9, 10], leaving the optimal timing debated.

The use of intraocular lens (IOL) implantation in children remains controversial, despite the well-established role in adult cataract surgery [11]. While some advocate delayed implantation ( $\geq 2$  years), demonstrating that primary IOL placement before 2 years increases risks of secondary glaucoma, visual axis opacification (VAO), and inflammation [12, 13]; Additionally, it offers no significant visual advantage over aphakic correction [14]. Others propose primary IOL implantation before 6 months reduced surgical burden (single-stage procedure),



© The Author(s) 2025. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

continuous optical correction, and mitigation of anisometropia in unilateral cases [15, 16]. This controversy underscores the need for evidence-based guidelines.

Furthermore, few studies have investigated the relationship between cataract phenotypes and postoperative outcomes. To address these gaps, this systematic review and meta-analysis evaluates amblyopia incidence following congenital cataract surgery, analyzes modifiable risk factors (surgical timing, IOL strategy), and provides clinical recommendations.

# Method

This meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [17, 18].

# Databases and search strategy

For this systematic review and meta-analysis, we searched PubMed, EMBASE, and the Cochrane Library for articles published between January 1, 1981, and March 1, 2023. Search terms included: "congenital cataract," "infantile cataract," "cataract extraction," "lensectomy," "IOL implantation," "amblyopia" and "lazy eye" in various combinations. Full search terms and the PRISMA flow diagram are provided in the Supplementary Material. (Literature search strategy and Supplementary Table 4).

### Eligibility and exclusion criteria

We included published articles reporting monocular and binocular visual outcomes after surgical intervention for congenital cataracts. The inclusion criterion for sight restoration intervention was cataract removal surgery followed by intraocular lens implantation. Congenital cataracts were defined as those diagnosed by a pediatrician or ophthalmologist within 30 days of birth. Additionally, articles were included if they (i) reported measures that allowed for the calculation of proportions (response rate) with a 95% confidence interval (CI); (ii) reported outcomes separately for unilateral and bilateral types of cataracts; (iii) reported the timing of cataract removal surgery and IOL implantation; (iv) reported preoperative diagnoses of cataract phenotype; (v) provided information on follow-up timing for each patient; and (vi) provided outcomes for postoperative complications. Studies were excluded if they (i) focused on populations with congenital cataracts in which the subjects were aged over 18 years of age at the time of surgery; (ii) focused on congenital cataracts secondary to genetic syndromes, metabolic disorders, or intrauterine infections; (iii) excluded patients with concurrent ocular congenital anomalies (e.g., microphthalmos, microcornea, ptosis, congenital glaucoma, Lowe syndrome, persistent hyperplastic primary vitreous (PHPV)/persistent fetal vasculature (PFV) or systemic birth defects; (iv) were not published within the date range of January 1, 1981, to March 1, 2023; (v) were not initially published in English. Quality assessment of the included studies was conducted independently by two researchers using the Newcastle–Ottawa Scale (NOS) [19]. The NOS evaluates quality across three domains, with a maximum score of 9. Studies scoring 7–9 were of high quality, while scores of 4–7 indicate moderate quality. Disagreements were resolved by a third author.

# Data extraction and statistical analysis

The extracted data included (i) type of article, (ii) country of origin, (iii) number of participants, (iv) clinical and ocular characteristics, (v) average age at surgical intervention, (vi) type of intervention(s), (vii) whether amblyopia treatment was administered postoperatively, (viii) postoperative follow-up timing, and (ix) suitability for the review and reason for exclusion. The key outcome of this study was the proportion of patients with congenital cataracts and low vision quality after surgical intervention. Amblyopia was defined based on criteria from the 2021 Expert Consensus in China [20] and the 2022 Clinical Practice Guidelines of the American Academy of Ophthalmology [21]. Statistical analyses were performed via single-arm meta-analyses using Stata version 16.0. A meta-analysis was conducted for each outcome reported in more than two studies. Heterogeneity among the included studies was evaluated using Cochran's Q statistic and the I2 index score. Values of I2 > 50% or P > 0.1 were considered indicative of high heterogeneity. When heterogeneity was high, a random-effects model (DerSimonian and Laird method) was used for analysis; otherwise, a fixed-effects model (inverse variance method) was used [18]. The pooled prevalence of postoperative amblyopia was calculated and the outcome was reported with a 95% confidence interval (CI). Subgroup analyses were conducted based on the timing of cataract removal surgery, IOL implantation, cataract phenotype, and followup duration. Sensitivity analysis was performed to assess the robustness of the main meta-analysis results. Publication bias was assessed using Egger's linear regression method. A P-value threshold of less than 0.05 was established for statistical significance.

# Results

# Study characteristics

Twenty-eight articles met our criteria for this systematic review and meta-analysis, including 1 randomized controlled trial (RCT) [22], 1 cohort study [23], 20 case series [6, 7, 15, 24–42], and 6 clinical trial studies [4, 38, 39, 43–45]. (Supplementary Tables 1 and 2 for the characteristics and quality evaluation of the included articles). A total of

2,167 patients were included, with 3,371 eyes included in our analysis (Fig. 1). Among them, 963 had unilateral congenital cataracts and 1,204 had bilateral congenital cataracts (Supplementary Table 3). Below, we describe the results for various groups in detail.

### Pooled amblyopia prevalence

We recorded the best-corrected visual acuity (BCVA) of all patients in each study reported at the final follow-up and measured the prevalence of amblyopia. The results revealed a pooled proportion of 62% for the presence of amblyopia after surgical intervention using a random-effects model (95% CI: 0.55–0.69,  $I^2 = 91.7\%$ ) (Fig. 2).

## Effect of cataract extraction timing

We categorized our subjects into four subgroups based on age at the time of surgical intervention. For patients who underwent surgery before 8 weeks, the proportion of patients with amblyopia was 53% (95% CI: [0.42, 0.64];  $I^2 = 8.6\%$ ). For those who underwent surgery between 8–12 weeks, the proportion was 56% (95% CI: [0.42, 0.70];  $I^2 = 63.0\%$ ). The proportion of patients who underwent surgery between 12 weeks and 12 months was 79% (95% CI: [0.69, 0.88];  $I^2 = 59.2\%$ ). The proportion of patients who underwent surgery after 12 months was 79% (95% CI: [0.68, 0.90];  $I^2 = 86.8\%$ ). There were statistically significant differences among the subgroups (*P* < 0.001) (Fig. 3A).

The results in the bilateral group were consistent with the trends observed in the unilateral group. For those who underwent surgery within 12 weeks, the proportion of patients with amblyopia was 39% (95% CI: [0.31, 0.47];  $I^2 = 0.00\%$ ). The prevalence rates for those who underwent surgery between 12 weeks and 12 months and those who underwent surgery after 12 months were 52% (95% CI: [0.46, 0.58];  $I^2 = 31.2\%$ ) and 71% (95% CI: [0.50,




Fig. 1 Flow diagram of the literature search and study selection process

Overall Prevalence of Amblyopia	Effect (95% CI)	Weight(%
Jean Jacques Aron 1983	0.92 (0.78, 1.06)	3.57
Elie Dahan 1990	0.92 (0.78, 1.07)	3.55
Kenneth P. Cheng 1991	0.76 (0.56, 0.97)	3.11
Steven Awner 1996	0.66 (0.39, 0.93)	2.60
S. M. Brown 1999	0.46 (0.19, 0.73)	2.58
Claude Speeg-Schatz 2005	0.65 (0.56, 0.74)	3.89
Rudolf Autrata 2005	0.61 (0.46, 0.76)	3.52
S. R. Lambert 2006	0.40 (0.25, 0.55)	3.54
H. H. Ye 2007	0.58 (0.42, 0.74)	3.46
Ledoux, D. M 2007	0.32 (0.24, 0.40)	3.97
HUSSIN HM 2009	0.75 (0.62, 0.88)	3.63
T. Yu 2009	0.77 (0.54, 1.00)	2.90
Gochnauer, A. C 2010	0.39 (0.27, 0.51)	3.73
D. H. Kim 2012	0.32 (0.17, 0.47)	3.50
H. Zhang 2012	➡ 0.60 (0.55, 0.64)	4.11
Hennig, A 2013	• 0.47 (0.42, 0.51)	4.09
Adriano Magli 2016	0.63 (0.54, 0.72)	3.92
E. Eugenie Hartmann 2014	0.48 (0.34, 0.62)	3.57
A. Magli 2015	0.79 (0.68, 0.90)	3.79
X. Rong 2015	0.60 (0.51, 0.69)	3.90
Negalur, M 2018	0.63 (0.48, 0.78)	3.51
J. Park 2018	0.95 (0.88, 1.02)	4.01
Yangzes, S 2019	0.53 (0.43, 0.63)	3.84
S. R. Lambert 2020	0.71 (0.59, 0.83)	3.72
Erick D Bothun 2021	0.47 (0.32, 0.62)	3.48
A. Beheshtnejad 2022	0.88 (0.79, 0.97)	3.92
Mari Kathrine Sand 2022	0.65 (0.46, 0.84)	3.16
David Wackerberg 2023	0.41 (0.25, 0.57)	3.43
Overall, DL (l² = 91.7%, p = 0.000)	0.62 (0.55, 0.69)	100.00
-1 0	1	

Fig. 2 Forest plot of the pooled proportion estimates of amblyopia following surgical intervention in congenital cataract, using a random-effects model. CI = confidence interval; DL = DerSimonian-Laird random-effects model

0.92];  $I^2 = 90.3\%$ ), respectively. There were statistically significant differences among the subgroups (P = 0.005) (Fig. 3B).

# Impact of IOL implantation timing

Comparing the prevalence of amblyopia among different IOL implantation groups, we observed a lower rate in the primary implantation group 61% (95% CI: [0.51, 0.71];  $I^2 = 90.7\%$ ) than in the secondary implantation group 66% (95% CI: [0.57, 0.74];  $I^2 = 90.2\%$ ) (Fig. 4A). However, no statistically significant difference were detected between these subgroups (P = 0.527). When categorized by the timing of IOL implantation-pre-12 weeks, between 12 weeks and 12 months, and post-12 months-the rates

(See figure on next page.)

Fig. 3 Forest plot of the pooled proportion of amblyopia following surgical intervention for the subgroups: A Age at the time of surgery before 8 weeks, 8–12 weeks, 12 weeks-12 months, and after 12 months within the unilateral congenital cataract group; B Age at the time of surgery before 12 weeks, 12 weeks-12 months, and after 12 months within the bilateral congenital cataract group. Subgroup analyses are presented with effect sizes (proportions), 95% confidence intervals (CI), and heterogeneity metrics (I<sup>2</sup> statistic and P-value). CI = confidence interval; DL = DerSimonian-Laird random-effects model

Unilateral congenital cataract g				
≤8 weeks				
Mari Kathrine Sand 2022	4.5w	-	0.65 (0.46, 0.84)	4.40
E. Eugenie Hartmann 2014	7w		0.48 (0.34, 0.62)	5.19
S. M. Brown 1999	8w		0.46 (0.19, 0.73)	3.40
Subgroup, DL (l <sup>2</sup> = 8.6%, p = 0.33	35)	$\diamond$	0.53 (0.42, 0.64)	12.99
8-12 weeks				
David Wackerberg 2023	10w	i	0.41 (0.25, 0.57)	4.9
Claude Speeg-Schatz 2005	12w		0.65 (0.51, 0.79)	5.2
Rudolf Autrata 2005	12w		0.61 (0.46, 0.76)	5.0
Subgroup, DL ( $I^2 = 63.0\%$ , p = 0.0		$\diamond$	0.56 (0.42, 0.70)	15.24
12 weeks-12 months		1		
Kenneth P. Cheng 1991	20w		0.76 (0.56, 0.97)	4.3
Negalur, M 2018	5m		0.77 (0.50, 1.04)	3.3
-	9m			5.6
A. Magli 2015			0.79 (0.68, 0.90)	
X. Rong 2015	8.32m		• 0.85 (0.73, 0.97)	5.4
Adriano Magli 2016	8.52m		0.63 (0.52, 0.74)	5.6
Elie Dahan 1990	11m		0.92 (0.78, 1.07)	5.1
Subgroup, DL (I <sup>2</sup> = 59.2%, p = 0.0	032)		> 0.79 (0.69, 0.88)	29.53
>12 months				
Steven Awner 1996	26m		0.67 (0.40, 0.94)	3.4
Jean Jacques Aron 1983	23m	i -	• 0.93 (0.79, 1.06)	5.2
HUSSIN HM 2009	13.03m		0.82 (0.66, 0.98)	4.9
Yangzes, S. 2019	13.23m		0.53 (0.43, 0.63)	5.74
H. Zhang 2012	58.6m	-	0.79 (0.73, 0.85)	6.18
J. Park 2018	72m	1	0.95 (0.88, 1.02)	6.1
A. Beheshtnejad 2022	27.32m		0.88 (0.73, 1.03)	5.1
	62.4m			5.4
S. R. Lambert 2020 Subgroup, DL (I <sup>2</sup> = 86.8%, p = 0.0		$\langle$	<ul> <li>0.71 (0.59, 0.83)</li> <li>0.79 (0.68, 0.90)</li> </ul>	42.2
		1		
Heterogeneity between groups: Overall, DL (I² = 84.0%, p = 0.00		∽	0.72 (0.65, 0.79)	100.00
Bilateral congenital cata	aract		Effect (95% CI)	Weigh
≤ 12 weeks				
Scott R. Lambert 2006			0.40 (0.05, 0.55)	7.5
	05		0.40 (0.25, 0.55)	
Claude Speeg-Schatz 20	05		0.44 (0.31, 0.57)	7.9
D. H. Kim 2012 Subgroup, DL (I <sup>2</sup> = 0.0%,	p = 0.495)	$\diamond$	0.32 (0.17, 0.47) 0.39 (0.31, 0.47)	7.4
12 weeks- 12 months				
Adriano Magli 2016			0.63 (0.49, 0.77)	7.6
H. H. Ye 2007			0.58 (0.42, 0.74)	7.2
Negalur, M. 2018			0.61 (0.44, 0.78)	6.8
X. Rong 2015			0.49 (0.38, 0.60)	8.5
Hennig, A. 2013			0.47 (0.42, 0.52)	10.0
Erick D Bothun 2021	- 0.001)	~	0.47 (0.32, 0.62)	7.3
Subgroup, DL (I <sup>2</sup> = 31.2%	p = 0.201		0.52 (0.46, 0.58)	47.5
> 12 months			0.00 /0.11	
HUSSIN HM 2009			- 0.66 (0.44, 0.88)	5.5
T. Yu 2009			0.77 (0.54, 1.00)	5.3
H. Zhang 2012		*	0.54 (0.48, 0.60)	9.9
A. Beheshtnejad 2022			• 0.88 (0.77, 0.99)	8.5
Subgroup, DL (I <sup>2</sup> = 90.3%	o, p = 0.000)		> 0.71 (0.50, 0.92)	29.4
Hotorogonoity botwoon	groups: p = 0.005			
Overall, DL (l <sup>2</sup> = 81.8%, p		1	0.55 (0.48, 0.63)	100.0

Fig. 3 (See legend on previous page.)

Stages of IOL Implantation	Effect (95% CI)	Weight(%
Primary Implantation		
Mari Kathrine Sand 2022	0.65 (0.46, 0.84)	2.89
E. Eugenie Hartmann 2014	0.48 (0.34, 0.62)	3.32
David Wackerberg 2023	0.41 (0.25, 0.57)	3.17
Rudolf Autrata 2005	0.61 (0.46, 0.76)	3.25
A. Magli 2015	0.79 (0.61, 0.97)	2.98
I. Park 2018	0.95 (0.88, 1.02)	3.79
HUSSIN HM 2009	0.82 (0.66, 0.98)	3.17
Gochnauer, A. C 2010	0.39 (0.27, 0.51)	3.48
/angzes, S 2019	0.53 (0.43, 0.63)	3.60
Negalur, M 2018	0.78 (0.51, 1.05)	2.31
Kenneth P. Cheng 1991	0.76 (0.56, 0.97)	2.84
Steven Awner 1996	0.67 (0.40, 0.93)	2.34
edoux, D. M 2007		3.47
IUSSIN HM 2009	0.66 (0.51, 0.81)	3.27
lennig, A 2013	• 0.47 (0.42, 0.52)	3.87
legalur, M 2018	0.61 (0.45, 0.77)	3.21
Frick D Bothun 2021	0.47 (0.32, 0.62)	3.21
Subgroup, DL (I <sup>2</sup> = 90.7%, p = 0.000)	0.61 (0.51, 0.71)	54.17
econdery Implantation		
A. Zhang 2012	0.59 (0.52, 0.66)	3.77
C. Rong 2015	0.85 (0.73, 0.97)	3.47
Adriano Magli 2016	0.63 (0.52, 0.74)	3.47
		3.54
S. R. Lambert 2020		
Claude Speeg-Schatz 2005	0.89 (0.80, 0.98)	3.68
lie Dahan 1990	0.92 (0.77, 1.07)	3.27
ean Jacques Aron 1983	0.92 (0.78, 1.06)	3.31
D. H. Kim 2012	0.32 (0.17, 0.47)	3.25
I. Zhang 2012	• 0.59 (0.55, 0.63)	3.89
K. Rong 2015	0.49 (0.40, 0.58)	3.65
driano Magli 2016	0.63 (0.54, 0.72)	3.69
I. H. Ye 2007	0.58 (0.42, 0.74)	3.19
Claude Speeg-Schatz 2005	0.44 (0.34, 0.54)	3.63
Subgroup, DL (I <sup>2</sup> = 90.2%, p = 0.000)	0.66 (0.57, 0.74)	45.83
ming of IOL Implantation	Effect (95% CI)	Weight(%
ari Kathrine Sand 2022	0.65 (0.46, 0.84)	3.12
Eugenie Hartmann 2014	0.48 (0.34, 0.62)	3.49
avid Wackerberg 2023 -		
	0.41 (0.25, 0.57)	
	0.41 (0.25, 0.57)	3.36
aude Speeg-Schatz 2005	0.65 (0.51, 0.79)	3.36 3.53
aude Speeg-Schatz 2005 Jdolf Autrata 2005		3.36
laude Speeg-Schatz 2005 udolf Autrata 2005 ubgroup, DL. (l² = 46.7%, p = 0.112)	0.65 (0.51, 0.79) 0.61 (0.46, 0.76)	3.36 3.53 3.44
aude Speeg-Schatz 2005 Jdolf Autrata 2005 Jubgroup, DL (l² = 46.7%, p = 0.112) 2 weeks-12 months	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65)	3.36 3.53 3.44 16.93
aude Speeg-Schatz 2005 Jdolf Autrata 2005 Jubgroup, DL (I <sup>2</sup> = 46.7%, p = 0.112) 2 weeks-12 months enneth P. Cheng 1991	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65)	3.36 3.53 3.44 16.93 3.07
aude Speeg-Schatz 2005 Jdolf Autrata 2005 Jbgroup, DL (P = 46.7%, p = 0.112) 2: weeks-12 months sneth P. Cheng 1991 agalur, M 2018	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09)	3.36 3.53 3.44 16.93 3.07 2.33
aude Speeg-Schatz 2005 Jdolf Autrata 2005 Jubgroup, DL (I <sup>a</sup> = 46.7%, p = 0.112) 2: weeks-12 months anneth P. Cheng 1991 agalur, M 2018 Magli 2015	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90)	3.36 3.53 3.44 16.93 3.07 2.33 3.68
aude Speeg-Schatz 2005 Jdolf Autrata 2005 Jubgroup, DL (l <sup>2</sup> = 46.7%, p = 0.112) 2 weeks-12 months anneth P. Cheng 1991 agalur, M 2018 Magli 2015 driano Magli 2016	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74)	3.36 3.53 3.44 16.93 3.07 2.33 3.68 3.69
aude Speeg-Schatz 2005 Jdolf Autrata 2005 bgroup, DL (# = 46.7%, p = 0.112) 2: weeks-12 months enreth P. Cheng 1991 egalur, M 2018 Magli 2015 Jriano Magli 2016 Rong 2015	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.65) 0.78 (0.47, 1.09) 0.79 (0.68, 0.97) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.79 (0.52, 0.74) 0.85 (0.52, 0.74)	3.36 3.53 3.44 16.93 3.07 2.33 3.68 3.69 3.63
aude Speeg-Schatz 2005 Jdolf Autrata 2005 bdgroup, DL (I <sup>p</sup> = 46.7%, p = 0.112) <b>2 weeks-12 months</b> anneth P. Cheng 1991 agalur, M 2018 Magli 2015 Jriano Magli 2016 Rong 2015 bott R. Lambert 2006	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.63 (0.52, 0.74) 0.63 (0.73, 0.97) 0.40 (0.25, 0.55)	3.36 3.53 3.44 16.93 3.07 2.33 3.68 3.69 3.63 3.46
aude Speeg-Schatz 2005 Jodgi Autrata 2005 Jogroup, DL (F = 46.7%, p = 0.112) 2 weeks-12 months enneth P. Cheng 1991 agalur, M 2018 Magli 2015 Jirano Magli 2016 Rong 2015 Sott R. Lambert 2006 aude Speeg-Schatz 2005	0.55 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.85 (0.73, 0.97) 0.40 (0.25, 0.55) 0.44 (0.23, 0.55)	3.36 3.53 3.44 16.93 3.07 2.33 3.68 3.69 3.63 3.46 3.56
aude Speeg-Schatz 2005 Jdolf Autrata 2005 Jdogroup, DL (# = 46.7%, p = 0.112) 2 weeks-12 months enneth P. Cheng 1991 egalur, M 2018 Magli 2015 Triano Magli 2016 Rong 2015 Soft R. Lambert 2006 aude Speeg-Schatz 2005 egalur, M 2018	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.65) 0.79 (0.47, 1.09) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.65 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.44 (0.31, 0.57) 0.61 (0.44, 0.78)	3.36 3.53 3.44 16.93 3.07 2.33 3.68 3.69 3.63 3.46 3.56 3.28
aude Speeg-Schatz 2005 Jdolf Autrata 2005 bdgroup, DL (I <sup>2</sup> = 46.7%, p = 0.112) 2 weeks-12 months anneth P. Cheng 1991 agalur, M 2018 Magli 2015 Jriano Magli 2016 Rong 2015 sott R. Lambert 2006 aude Speeg-Schatz 2005 agalur, M 2018 Triano Magli 2016	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.65) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.65 (0.573, 0.97) 0.44 (0.78) 0.44 (0.37) 0.63 (0.44, 0.78) 0.63 (0.49, 0.77)	3.36 3.53 3.44 16.93 3.07 2.33 3.68 3.69 3.63 3.46 3.56 3.28 3.47
aude Speeg-Schatz 2005 Jodoff Autrata 2005 Jobgroup, DL (F = 46.7%, p = 0.112) 2 weeks-12 months anneth P. Cheng 1991 agalur, M 2018 Magli 2015 Jirano Magli 2016 Rong 2015 Sott R. Lambert 2006 Jub Berge-Schatz 2005 Spalur, M 2018 Jirano Magli 2016 Spalur, M 2018 Jirano Magli 2016 Spalur, M 2018 Jirano Magli 2016	0.65 (0.51, 0.79) 0.61 (0.46, 0.65) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.63 (0.52, 0.74) 0.65 (0.73, 0.97) 0.40 (0.25, 0.55) 0.44 (0.25, 0.55) 0.61 (0.44, 0.78) 0.63 (0.49, 0.77) 0.63 (0.42, 0.52)	3.36 3.53 3.44 16.93 3.07 2.33 3.68 3.69 3.63 3.46 3.56 3.28 3.47 3.96
aude Speeg-Schatz 2005 dolf Autrata 2005 bgroup, DL (# = 46.7%, p = 0.112) 2 weeks-12 months enneth P. Cheng 1991 egalur, M 2018 Magli 2015 triano Magli 2016 Rong 2015 cott R. Lambert 2006 aude Speeg-Schatz 2005 ordi R. Lambert 2006 ande Speeg-Schatz 2005 egalur, M 2018 triano Magli 2016 ennig, A 2013 tok D Bothun 2021	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.65) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.44 (0.31, 0.57) 0.44 (0.31, 0.57) 0.47 (0.42, 0.52) 0.47 (0.42, 0	3.36 3.53 3.44 16.93 3.07 2.33 3.68 3.69 3.63 3.46 3.56 3.28 3.46 3.56 3.28 3.47 3.96 3.40
aude Speeg-Schatz 2005 dolf Autrata 2005 bgroup, DL (# = 46.7%, p = 0.112) 2 weeks-12 months enneth P. Cheng 1991 egalur, M 2018 Magli 2015 triano Magli 2016 Rong 2015 cott R. Lambert 2006 aude Speeg-Schatz 2005 ordi R. Lambert 2006 ande Speeg-Schatz 2005 egalur, M 2018 triano Magli 2016 ennig, A 2013 tok D Bothun 2021	0.65 (0.51, 0.79) 0.61 (0.46, 0.65) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.63 (0.52, 0.74) 0.65 (0.73, 0.97) 0.40 (0.25, 0.55) 0.44 (0.25, 0.55) 0.61 (0.44, 0.78) 0.63 (0.49, 0.77) 0.63 (0.42, 0.52)	3.36 3.53 3.44 16.93 3.07 2.33 3.68 3.69 3.63 3.46 3.56 3.28 3.47 3.96
laude Speeg-Schatz 2005 udolf Autrata 2005 udolf Autrata 2005 2 weeks-12 months enneth P. Cheng 1991 egalur, M 2018 Magli 2015 driano Magli 2016 Rong 2015 cott R. Lambert 2006 egalur, M 2018 driano Magli 2016 ennig, A 2013 tot D Bothun 2021 ubgroup, DL (I <sup>a</sup> = 85.6%, p = 0.000) 12 months	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.55) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.63 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.44 (0.31, 0.57) 0.44 (0.31, 0.57) 0.47 (0.42, 0.52) 0.47 (0.51, 0.71)	3.36 3.53 3.44 16.93 3.07 2.33 3.68 3.69 3.63 3.46 3.56 3.28 3.46 3.56 3.24 3.40 3.7.53
aude Speeg-Schatz 2005 Jdolf Autrata 2005 Jdolf Autrata 2005 weeks-12 months smeth P. Cheng 1991 agalur, M 2018 Magli 2015 Striano Magli 2016 Rong 2015 Soft R. Lambert 2006 aude Speeg-Schatz 2005 Sgalur, M 2018 Jriano Magli 2016 annig, A 2013 Galar, M 2018 Jriano Magli 2016 annig, A 2013 Joint B. Striano Justic D Bothun 2021 Justic	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.65) 0.76 (0.46, 0.65) 0.76 (0.47, 1.09) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.63 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.47 (0.44, 0.78) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.32, 0.62) 0.61 (0.51, 0.71) 0.82 (0.66, 0.98)	3.36 3.53 3.44 16.93 3.07 2.33 3.68 3.69 3.63 3.46 3.28 3.46 3.28 3.47 3.96 3.40 37.53
aude Speeg-Schatz 2005 Jodoff Autrata 2005 Jobgroup, DL (# = 46.7%, p = 0.112) 2 weeks-12 months membt P. Cheng 1991 agalur, M 2018 Magli 2015 Jirano Magli 2016 Rong 2015 Scott R. Lambert 2006 aude Speeg-Schatz 2005 agalur, M 2018 Jirano Magli 2016 amig, A 2013 tick D Bothun 2021 Jubgroup, DL (# = 85.6%, p = 0.000) 2 months USSIN HM 2009 Ingzes, S. 2019	0.55 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.76 (0.56, 0.97) 0.79 (0.47, 1.09) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.44 (0.31, 0.57) 0.44 (0.31, 0.57) 0.44 (0.31, 0.57) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.53 (0.43, 0.63) 0.53 (0.43, 0.63)	3.36 3.53 3.44 16.93 3.67 2.33 3.68 3.69 3.63 3.46 3.56 3.28 3.47 3.96 3.40 37.53 3.36 3.74
aude Speeg-Schatz 2005 Jobif Autrata 2005 Jobgroup, DL (# = 46.7%, p = 0.112) 2: weeks-12 months enneth P. Cheng 1991 agalur, M 2018 Magli 2015 Triano Magli 2016 Rong 2015 Soft R. Lambert 2006 July 2018 Jriano Magli 2016 ande Speeg-Schatz 2005 agalur, M 2018 Jriano Magli 2016 angl, A 2018 Jriano Magli 2016 angl, A 2013 Jick D Bothun 2021 July 2013 July 2013 July 2014 July 2015 July	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.63 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.40 (0.23, 0.55) 0.44 (0.31, 0.57) 0.47 (0.32, 0.62) 0.61 (0.44, 0.78) 0.63 (0.49, 0.77) 0.47 (0.32, 0.62) 0.53 (0.43, 0.63) 0.53 (0.43, 0.63) 0.53 (0.43, 0.63) 0.65 (0.54, 0.98) 0.53 (0.43, 0.63) 0.66 (0.39, 0.33) 0.66 (0.39, 0.33)	3.36 3.53 16.93 3.69 3.69 3.63 3.66 3.56 3.28 3.40 3.56 3.28 3.40 3.753 3.36 3.40 3.753
aude Speeg-Schatz 2005 Jdolf Autrata 2005 Jdolf Autrata 2005 weeks-12 months seneth P. Cheng 1991 agalur, M 2018 Magli 2015 Striano Magli 2016 Rong 2015 Soft R. Lambert 2006 aude Speeg-Schatz 2005 sepalur, M 2018 Striano Magli 2016 amenig, A 2013 Striano Magli 2016 amenig, A 2013 Striano Magli 2016 Striano Magli 2017 Striano Magli 2017 Striano Magli 2018 Striano M	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.65) 0.76 (0.46, 0.65) 0.76 (0.47, 1.09) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.65 (0.73, 0.97) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.41 (0.44, 0.78) 0.63 (0.44, 0.78) 0.61 (0.51, 0.71) 0.61 (0.51, 0.71) 0.61 (0.51, 0.71) 0.62 (0.66, 0.98) 0.53 (0.43, 0.63) 0.66 (0.39, 0.83) 0.92 (0.78, 1.06)	3.36 3.53 3.44 16.93 3.69 3.69 3.69 3.69 3.66 3.28 3.46 3.56 3.28 3.47 3.96 3.40 3.753 3.36 3.74 2.59 3.49
aude Speeg-Schatz 2005 Jodif Autrata 2005 Jogroup, DL (F = 46.7%, p = 0.112) 2 weeks-12 months membt P. Cheng 1991 agalur, M 2018 Magli 2015 Jirano Magli 2016 Rong 2015 Scott R. Lambert 2006 aude Speeg-Schatz 2005 agalur, M 2018 Jirano Magli 2016 emig, A 2013 ick D Bothun 2021 Jubgroup, DL (F = 85.6%, p = 0.000) 2 months USSIN HM 2009 Ingzes, S. 2019 even Awner 1996 an Jacques Aron 1983 Rong 2015	0.55 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.79 (0.47, 1.09) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.25, 0.55) 0.44 (0.23, 0.57) 0.63 (0.49, 0.77) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.62) 0.61 (0.51, 0.77) 0.47 (0.42, 0.62) 0.61 (0.51, 0.71) 0.47 (0.42, 0.62) 0.61 (0.51, 0.71) 0.47 (0.42, 0.62) 0.53 (0.43, 0.63) 0.66 (0.39, 0.93) 0.92 (0.78, 1.06) 0.92 (0.78, 1.06) 0.92 (0.78, 1.06) 0.92 (0.78, 1.06)	3.36 3.53 3.44 16.93 3.69 3.69 3.68 3.69 3.66 3.26 3.28 3.46 3.56 3.28 3.47 3.96 3.40 37.53 3.40 37.53 3.36 3.74 2.59 3.49 3.63
aude Speeg-Schatz 2005 Jobif Autrata 2005 Jobgroup, DL (# = 46.7%, p = 0.112) 2: weeks-12 months emeth P. Cheng 1991 agalur, M 2018 Magli 2015 Triano Magli 2016 Rong 2015 Soft R. Lambert 2006 aude Speeg-Schatz 2005 agalur, M 2018 Jriano Magli 2016 anig, A 2013 ick D Bothun 2021 Job Schatz 2005 Jamig, A 2013 Justice D Bothun 2021 Job Schatz 2005 Jamig, A 2013 Justice D Bothun 2021 Job Schatz 2005 Jamig, A 2019 wen Awner 1996 an Jacques Aron 1983 Rog 2015 Zhang 2012	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.63 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.40 (0.23, 0.55) 0.44 (0.31, 0.57) 0.47 (0.32, 0.62) 0.53 (0.43, 0.63) 0.63 (0.49, 0.77) 0.47 (0.32, 0.62) 0.53 (0.43, 0.63) 0.53 (0.43, 0.63) 0.56 (0.39, 0.93) 0.52 (0.76, 1.06) 0.55 (0.73, 0.97) 0.79 (0.73, 0.85) 0.79 (0.73, 0.85) 0.75 (0.75, 0.75) 0.75 (0.75) 0.75 (	3.36 3.53 3.44 16.93 3.69 3.69 3.69 3.69 3.66 3.28 3.46 3.56 3.28 3.47 3.96 3.40 3.753 3.36 3.74 2.59 3.49
laude Speeg-Schatz 2005 udolf Autrata 2005 udolf Autrata 2005 ubgroup, DL (I° = 46.7%, p = 0.112) 2 weeks-12 months enneth P. Cheng 1991 egalur, M 2018 Magli 2015 triano Magli 2016 Rong 2015 cott R. Lambert 2006 aude Speeg-Schatz 2005 egalur, M 2018 triano Magli 2016 ennig, A 2013 tick D Bothun 2021 ubgroup, DL (I° = 85.6%, p = 0.000) 12 months USSIN HM 2009 angazes, S. 2019 even Awner 1996 an Jacques Aron 1983 Roag 2015 Zhang 2015 Zhang 2015	0.55 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.79 (0.47, 1.09) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.25, 0.55) 0.44 (0.23, 0.57) 0.63 (0.49, 0.77) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.62) 0.61 (0.51, 0.77) 0.47 (0.42, 0.62) 0.61 (0.51, 0.71) 0.47 (0.42, 0.62) 0.61 (0.51, 0.71) 0.47 (0.42, 0.62) 0.53 (0.43, 0.63) 0.66 (0.39, 0.93) 0.92 (0.78, 1.06) 0.92 (0.78, 1.06) 0.92 (0.78, 1.06) 0.92 (0.78, 1.06)	3.36 3.53 3.44 16.93 3.69 3.69 3.68 3.69 3.66 3.26 3.28 3.46 3.56 3.28 3.47 3.96 3.40 37.53 3.40 37.53 3.36 3.74 2.59 3.49 3.63
laude Speeg-Schatz 2005 udolf Autrata 2005 udolf Autrata 2005 2 weeks-12 months anneth P. Cheng 1991 agalur, M 2018 Magli 2015 Striano Magli 2016 Rong 2015 2017 R. Lambert 2006 aude Speeg-Schatz 2005 agalur, M 2018 driano Magli 2016 ennig, A 2013 ick D Bothun 2021 ubgroup, DL (I <sup>II</sup> = 85.6%, p = 0.000) 12 months USSIN HM 2009 angzes, S. 2019 even Awner 1996 ean Jacques Aron 1983 Rong 2012 Park 2018	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.63 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.40 (0.23, 0.55) 0.44 (0.31, 0.57) 0.47 (0.32, 0.62) 0.61 (0.44, 0.78) 0.63 (0.49, 0.77) 0.47 (0.32, 0.62) 0.53 (0.43, 0.63) 0.63 (0.43, 0.63) 0.63 (0.43, 0.63) 0.64 (0.39, 0.98) 0.53 (0.43, 0.63) 0.53 (0.43, 0.63) 0.53 (0.43, 0.63) 0.56 (0.39, 0.93) 0.52 (0.74, 1.06) 0.53 (0.73, 0.97) 0.53 (0.73, 0.97) 0.53 (0.73, 0.97) 0.55 (0.73, 0.97) 0.56 (0.73, 0.97) 0.57 (0.73, 0.85) 0.59 (0.73, 0.97) 0.59 (0.73, 0.85) 0.59 (0.73, 0.97) 0.59 (0.73, 0.85) 0.59 (0.73, 0.97) 0.59 (0.73, 0.85) 0.59 (0.73, 0.97) 0.59 (0.74, 0.97) 0.59 (0.73, 0.97) 0.59 (0.74, 0.97) 0.59 (0.75, 0.57) 0.59 (0.73, 0.97) 0.59 (0.75, 0.57) 0.59 (0.75, 0	3.36 3.53 3.44 16.93 3.69 3.63 3.69 3.63 3.66 3.28 3.40 3.56 3.28 3.40 3.753 3.36 3.40 3.753 3.36 3.74 2.59 3.49 3.69 3.92
laude Speeg-Schatz 2005 Judoff Autrata 2005 Judoff Autrata 2005 Judoff Autrata 2005 Judoff Autrata 2005 Seveeks-12 months enneth P. Cheng 1991 egalur, M 2018 Magli 2015 Jirano Magli 2016 Rong 2015 Scott R. Lambert 2006 egalur, M 2018 driano Magli 2016 egalur, M 2018 Jirano Magli 2016 egalur, M 2018 Jirano Magli 2016 egalur, M 2018 Judof Speeg-Schatz 2005 egalur, M 2018 Jirano Magli 2016 egalur, M 2018 Judof Speeg-Schatz 2005 egalur, M 2018 Judof Speeg-Schatz 2005 Judof Speeg-Schatz 2005 Ju	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.65 (0.73, 0.97) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.41 (0.44, 0.78) 0.63 (0.44, 0.78) 0.63 (0.44, 0.78) 0.61 (0.51, 0.71) 0.61 (0.51, 0.71) 0.61 (0.51, 0.71) 0.61 (0.51, 0.71) 0.61 (0.51, 0.71) 0.62 (0.66, 0.98) 0.53 (0.43, 0.63) 0.66 (0.73, 0.97) 0.50 (0.43, 0.63) 0.65 (0.73, 0.97) 0.50 (0.43, 0.63) 0.65 (0.73, 0.97) 0.50 (0.43, 0.63) 0.65 (0.73, 0.97) 0.50 (0.73, 0.85) 0.70 (0.73, 0.85) 0.75 (0.73, 0.97) 0.75 (0.73, 0.97) 0.75 (0.73, 0.85) 0.75 (0.73, 0.97) 0.75 (0.73, 0.97) 0.75 (0.73, 0.85) 0.75 (0.73, 0.97) 0.75 (0.73, 0.85) 0.75 (0.73, 0.97) 0.75 (0.73, 0.85) 0.75 (0.73, 0.97) 0.75 (0.73, 0.97) 0.75 (0.73, 0.85) 0.75 (0.73, 0.97) 0.75 (0.73, 0.97) 0.75 (0.73, 0.97) 0.75 (0.73, 0.97) 0.75 (0.73, 0.97) 0.75 (0.73, 0.97) 0.75 (0.75, 0.75) 0.75 (0.73, 0.97) 0.75 (0.75) 0.75 (0.75)	3.36 3.53 3.44 16.93 3.69 3.69 3.69 3.69 3.66 3.28 3.46 3.56 3.28 3.47 3.96 3.40 3.75 3.36 3.74 2.59 3.49 3.63 3.49 3.63 3.92 3.89
laude Speeg-Schatz 2005 udolf Autrata 2005 udolf Autrata 2005 bgroup, DL (I <sup>P</sup> = 46.7%, p = 0.112) 2 weeks-12 months aneth P. Cheng 1991 egalur, M 2018 Magli 2015 triano Magli 2016 Rong 2015 cott R. Lambert 2006 aude Speeg-Schatz 2005 egalur, M 2018 triano Magli 2016 ennig, A 2013 tick D Bothun 2021 ubgroup, DL (I <sup>P</sup> = 85.6%, p = 0.000) 12 months USSIN HM 2009 anguzes, S. 2019 teven Awner 1996 ana Jacques Aron 1983 Rong 2015 Zhang 2012 Park 2018 R, Lambert 2020 cothnauer, A. C 2010	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.63 (0.52, 0.74) 0.63 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.47 (0.32, 0.62) 0.53 (0.43, 0.63) 0.63 (0.43, 0.63) 0.63 (0.43, 0.63) 0.53 (0.43, 0.63) 0.59 (0.73, 0.98) 0.53 (0.43, 0.63) 0.50 (0.73, 0.98) 0.53 (0.43, 0.63) 0.50 (0.73, 0.98) 0.53 (0.43, 0.63) 0.50 (0.73, 0.98) 0.53 (0.43, 0.63) 0.50 (0.73, 0.98) 0.50 (0.73, 0.85) 0.50 (0.88, 1.02) 0.71 (0.59, 0.83) 0.59 (0.81, 0.97)	3.36 3.53 3.44 16.93 3.68 3.69 3.68 3.69 3.63 3.46 3.56 3.28 3.47 3.96 3.40 37.53 3.40 37.53 3.40 3.753 3.40 3.753 3.40 3.74 2.59 3.63 3.63 3.63
laude Speeg-Schatz 2005 udolf Autrata 2005 udolf Autrata 2005 ubgroup, DL (I <sup>II</sup> = 46.7%, p = 0.112) 2 weeks-12 months aneth P. Cheng 1991 agalur, M 2018 Magli 2015 driano Magli 2016 Rong 2015 cott R. Lambert 2006 aude Speeg-Schatz 2005 agalur, M 2018 driano Magli 2016 annig, A 2013 tick D Bothun 2021 ubgroup, DL (I <sup>II</sup> = 85.6%, p = 0.000) 12 months USSIN HM 2009 angzes, S. 2019 even Awner 1996 ban Jacques Aron 1983 Rong 2012 Park 2018 R. Lambert 2020 ochnauer, A. C 2010 USSIN HM 2009	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.55) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.70 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.41 (0.44, 0.78) 0.63 (0.49, 0.77) 0.47 (0.42, 0.52) 0.47 (0.32, 0.62) 0.53 (0.43, 0.63) 0.66 (0.39, 0.93) 0.55 (0.73, 0.97) 0.51 (0.73, 0.85) 0.52 (0.74, 1.06) 0.55 (0.73, 0.97) 0.71 (0.59, 0.83) 0.95 (0.88, 1.02) 0.71 (0.59, 0.83) 0.68 (0.81, 0.97) 0.56 (0.84, 0.88) 0.66 (0.44, 0.88)	3.36 3.53 3.44 16.93 3.69 3.69 3.69 3.69 3.66 3.28 3.46 3.56 3.28 3.47 3.96 3.40 3.75 3.96 3.74 2.59 3.49 3.63 3.63 3.89 3.63 3.89 3.63 3.80
laude Speeg-Schatz 2005 Judoff Autrata 2005 Judoff Autrata 2005 Judoff Autrata 2005 Judoff Autrata 2005 Judoff Autrata 2005 2 weeks-12 months enneth P. Cheng 1991 egalur, M 2018 Magli 2015 Jirano Magli 2016 Rong 2015 Scott R. Lambert 2006 Galaxies Speeg-Schatz 2005 ogalur, M 2018 Jirano Magli 2016 ennig, A 2013 Tick D Bothun 2021 Judoff Bothun 20	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.79 (0.47, 0.99) 0.79 (0.47, 0.99) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.63 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.32, 0.63) 0.63 (0.43, 0.63) 0.63 (0.43, 0.63) 0.65 (0.73, 0.97) 0.79 (0.78, 1.06] 0.55 (0.74, 0.97) 0.79 (0.78, 0.65) 0.99 (0.78, 1.06] 0.56 (0.74, 0.97) 0.79 (0.78, 0.85) 0.99 (0.78, 0.97) 0.46 (0.59, 0.83) 0.99 (0.81, 0.97) 0.56 (0.44, 0.88) 0.97 (0.59, 0.88) 0.99 (0.81, 0.97) 0.56 (0.44, 0.88) 0.97 (0.57, 0.97) 0.56 (0.44, 0.88) 0.59 (0.77, 0.97) 0.56 (0.44, 0.88) 0.59 (0.77, 0.97) 0.56 (0.74, 0.97) 0.56 (0.44, 0.88) 0.59 (0.77, 0.97) 0.56 (0.44, 0.88) 0.59 (0.77, 0.97) 0.56 (0.44, 0.88) 0.59 (0.77, 0.47) 0.56 (0.44, 0.88) 0.59 (0.77, 0.97) 0.56 (0.77, 0.97) 0.57 (0.77, 0.77) 0.57 (0.77) 0.57 (0.77) 0.57 (0.57) 0.57 (0.77) 0.57 (0.77)	3.36 3.53 3.44 16.93 3.69 3.68 3.69 3.63 3.46 3.56 3.28 3.47 3.96 3.40 37.53 3.40 37.53 3.40 3.753 3.40 3.74 2.59 3.49 3.63 3.86 3.82 3.89 3.63 3.86 3.86 3.88 4.23
laude Speeg-Schatz 2005 udolf Autrata 2005 udolf Autrata 2005 ubgroup, DL (I° = 46.7%, p = 0.112) 2 weeks-12 months enath P. Cheng 1991 egalur, M 2018 Magli 2015 driano Magli 2016 Rong 2015 cott R. Lambert 2006 Magli 2016 Magli 2017 Magli 2018 Magli 2018 Magli 2019 teven Awner 1996 Magli 2015 Magli 2012 Magli 2018 Magli 2018	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.63 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.25, 0.55) 0.44 (0.31, 0.57) 0.61 (0.44, 0.78) 0.63 (0.49, 0.77) 0.47 (0.32, 0.62) 0.47 (0.32, 0.62) 0.53 (0.43, 0.63) 0.63 (0.43, 0.63) 0.63 (0.43, 0.63) 0.63 (0.43, 0.63) 0.63 (0.43, 0.63) 0.63 (0.43, 0.63) 0.65 (0.73, 0.97) 0.53 (0.43, 0.63) 0.62 (0.74, 0.51) 0.53 (0.43, 0.63) 0.56 (0.73, 0.97) 0.57 (0.73, 0.85) 0.57 (0.73, 0.85) 0.57 (0.85, 1.02) 0.77 (0.59, 0.83) 0.59 (0.81, 0.97) 0.66 (0.44, 0.88) 0.52 (0.74, 0.87) 0.59 (0.83, 0.67) 0.59 (0.84, 0.63) 0.59 (0.84, 0.67) 0.59 (0.54, 0.57) 0.59 (0.54, 0	3.36 3.53 3.44 16.93 3.69 3.63 3.69 3.63 3.66 3.56 3.28 3.40 37.53 3.96 3.40 37.53 3.36 3.74 2.59 3.49 3.63 3.92 3.89 3.63 3.86 2.94 3.86 2.94 3.67
laude Speeg-Schatz 2005 udolf Autrata 2005 udolf Autrata 2005 ubgroup, DL (I* = 46.7%, p = 0.112) 2 weeks-12 months enath P. Cheng 1991 egalur, M 2018 . Magli 2015 driano Magli 2016 . Rong 2015 cott R. Lambert 2006 adude Speeg-Schatz 2005 egalur, M 2018 driano Magli 2016 ennig, A 2013 rick D Bothun 2021 ubgroup, DL (I* = 85.6%, p = 0.000) 12 months USSIN HM 2009 an Jacques Aron 1983 . Rong 2015 . Zhang 2012 Park 2018 R. Lambert 2020 ochnauer, A. C 2010 USSIN HM 2009 H. Kim 2012 . Rong 2015 . H. Ye 2007 ubgroup, DL (I* = 90.8%, p = 0.000)	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.76 (0.56, 0.97) 0.79 (0.47, 0.99) 0.79 (0.47, 0.99) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.63 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.63 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.42, 0.52) 0.47 (0.32, 0.63) 0.63 (0.43, 0.63) 0.63 (0.43, 0.63) 0.65 (0.73, 0.97) 0.79 (0.78, 1.06] 0.55 (0.74, 0.97) 0.79 (0.78, 0.65) 0.99 (0.78, 1.06] 0.56 (0.74, 0.97) 0.79 (0.78, 0.85) 0.99 (0.78, 0.97) 0.46 (0.59, 0.83) 0.99 (0.81, 0.97) 0.56 (0.44, 0.88) 0.97 (0.59, 0.88) 0.99 (0.81, 0.97) 0.56 (0.44, 0.88) 0.97 (0.57, 0.97) 0.56 (0.44, 0.88) 0.59 (0.77, 0.97) 0.56 (0.44, 0.88) 0.59 (0.77, 0.97) 0.56 (0.74, 0.97) 0.56 (0.44, 0.88) 0.59 (0.77, 0.97) 0.56 (0.44, 0.88) 0.59 (0.77, 0.97) 0.56 (0.44, 0.88) 0.59 (0.77, 0.47) 0.56 (0.44, 0.88) 0.59 (0.77, 0.97) 0.56 (0.77, 0.97) 0.57 (0.77, 0.77) 0.57 (0.77) 0.57 (0.77) 0.57 (0.57) 0.57 (0.77) 0.57 (0.77)	3.36 3.53 3.44 16.93 3.69 3.68 3.69 3.63 3.46 3.56 3.28 3.47 3.96 3.40 37.53 3.40 37.53 3.40 3.753 3.40 3.74 2.59 3.49 3.63 3.86 3.82 3.89 3.63 3.86 3.86 3.88 4.23
laude Speeg-Schatz 2005 udolf Autrata 2005 udolf Autrata 2005 ubgroup, DL (l° = 46.7%, p = 0.112) 2 weeks-12 months enneth P. Cheng 1991 egalur, M 2018 . Magli 2015 driano Magli 2016 . Rong 2015 cott R. Lambert 2006 aude Speeg-Schatz 2005 egalur, M 2018 driano Magli 2016 . India Speeg-Schatz 2005 . India	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.55) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.70 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.41 (0.44, 0.78) 0.42 (0.52) 0.47 (0.32, 0.62) 0.47 (0.32, 0.62) 0.47 (0.32, 0.63) 0.66 (0.39, 0.93) 0.55 (0.73, 0.97) 0.55 (0.73, 0.97) 0.55 (0.73, 0.97) 0.55 (0.73, 0.97) 0.57 (0.73, 0.85) 0.57 (0.73, 0.85) 0.59 (0.88, 1.02) 0.71 (0.59, 0.83) 0.49 (0.38, 0.60) 0.49 (0.38, 0.60) 0.49 (0.38, 0.60) 0.58 (0.42, 0.74)	3.36 3.53 3.44 16.93 3.69 3.69 3.69 3.63 3.46 3.56 3.28 3.47 3.96 3.40 3.74 2.59 3.49 3.63 3.63 3.63 3.89 3.63 3.89 3.63 3.89 3.63 3.89 3.63 3.89 3.63 3.89 3.63 3.89 3.63
laude Speeg-Schatz 2005 udolf Autrata 2005 udolf Autrata 2005 ubgroup, DL (I° = 46.7%, p = 0.112) 2 weeks-12 months enath P. Cheng 1991 egalur, M 2018 .Magli 2015 driano Magli 2016 .Rong 2015 cott R. Lambert 2006 egalur, M 2018 driano Magli 2016 . Rong 2015 . Lambert 2006 . egalur, M 2018 driano Magli 2016 . ennig, A 2013 rick D Bothun 2021 . ubgroup, DL (I° = 85.6%, p = 0.000) 12 months USSIN HM 2009 angzes, S. 2019 San Jacques Aron 1983 . Rong 2012 . Park 2018 . R. Lambert 2020 cohnauer, A. C 2010 USSIN HM 2009 . H. Kim 2012 . Rong 2015 . H. Ye 2007	0.65 (0.51, 0.79) 0.61 (0.46, 0.76) 0.56 (0.46, 0.65) 0.56 (0.46, 0.55) 0.76 (0.56, 0.97) 0.78 (0.47, 1.09) 0.79 (0.68, 0.90) 0.79 (0.68, 0.90) 0.70 (0.52, 0.74) 0.40 (0.25, 0.55) 0.44 (0.31, 0.57) 0.41 (0.44, 0.78) 0.42 (0.52) 0.47 (0.32, 0.62) 0.47 (0.32, 0.62) 0.47 (0.32, 0.63) 0.66 (0.39, 0.93) 0.55 (0.73, 0.97) 0.55 (0.73, 0.97) 0.55 (0.73, 0.97) 0.55 (0.73, 0.97) 0.57 (0.73, 0.85) 0.57 (0.73, 0.85) 0.59 (0.88, 1.02) 0.71 (0.59, 0.83) 0.49 (0.38, 0.60) 0.49 (0.38, 0.60) 0.49 (0.38, 0.60) 0.58 (0.42, 0.74)	3.36 3.53 3.44 16.93 3.69 3.69 3.69 3.63 3.46 3.56 3.28 3.47 3.96 3.40 3.74 2.59 3.49 3.63 3.63 3.63 3.89 3.63 3.89 3.63 3.89 3.63 3.89 3.63 3.89 3.63 3.89 3.63 3.89 3.63

Fig. 4 Forest plot of the pooled proportion of amblyopia following IOL implantation for the subgroups: A Primary implantation versus secondary implantation; B Subgroup categorized by IOL implantation timing: Before 12 weeks, 12 weeks-12 months, and after 12 months. Subgroup analyses are presented with effect sizes (proportions), 95% confidence intervals (CI), and heterogeneity metrics ( $I^2$  statistic and *P*-value). CI = confidence interval; DL = DerSimonian-Laird random-effects model

of amblyopia were 56% (95% CI: [0.46, 0.65];  $I^2 = 46.7\%$ ), 61% (95% CI: [0.51, 0.71];  $I^2 = 85.6\%$ ), and 71% (95% CI: [0.61, 0.81];  $I^2 = 90.8\%$ ), respectively. However, no significant differences were observed among the subgroups (P = 0.096) (Fig. 4B).

# Cataract phenotype and amblyopia risk

To assess the influence of cataract phenotype on postoperative visual acuity, we categorized the preoperative diagnoses into four groups: unilateral complete obstruction, unilateral partial obstruction, bilateral complete obstruction, and bilateral partial obstruction. Our analysis revealed a higher prevalence of amblyopia in the unilateral complete obstruction group, reaching 69% (95% CI: [0.47, 0.91]; I<sup>2</sup> = 89.2%), followed by unilateral partial obstruction with a prevalence of 68% (95% CI: [0.47, 0.90]; I<sup>2</sup> = 84.5%).

For bilateral cataracts, the prevalence rates of complete and partial obstruction were 38% (95% CI: [0.28, 0.48];  $I^2 = 50.8\%$ ) and 36% (95% CI: [0.25, 0.47];  $I^2 = 43.0\%$ ), respectively. We compared the occurrence across the four classifications. Significant differences were found between unilateral partial obstruction and bilateral complete obstruction (P = 0.01) and partial obstruction (P =0.008) and between unilateral complete obstruction and bilateral complete obstruction (P = 0.009) and partial obstruction (P = 0.007) (Fig. 5A).

Using an alternative classification method, we categorized cataract phenotypes into four groups: Total, Nuclear, Posterior Subcapsular, and Other (including lamellar, anterior polar, punctate, and other opacities) to examine the prevalence of amblyopia in patients. Subgroup analysis results showed that the prevalence of amblyopia in the total cataract group was slightly higher than that in the other subgroups; however, no significant differences were observed among them (P = 0.725) (Fig. 5B).

### Follow-up duration and age at last assessment

Our analysis of the relationship between follow-up duration and postoperative visual outcomes revealed prevalence rates of 75% (95% CI: [0.60,0.91],  $I^2 = 96.4\%$ ) for less than 4 years, 64% (95% CI: [0.53,0.75],  $I^2 = 82.6\%$ ) for 4–8 years, and 65% (95% CI: [0.52,0.77],  $I^2 = 88.8\%$ ) for  $\geq$  8 years. However, no statistically significant correlation was observed among the subgroups (*P* = 0.444) (Fig. 6A).

Additionally, we conducted another subgroup analysis based on age at the last follow-up, dividing patients into two groups with a cutoff age of 6 years, to investigate whether tracking specific ages correlates with long-term visual recovery. Our results showed a 69% prevalence rate of amblyopia (95% CI: [0.60,0.78],  $I^2 = 91.9\%$ ) for children followed up beyond the age of 6, while for those followed up at or below 6 years old, it was 66% (95% CI: [0.52,0.79],  $I^2 = 91.6\%$ ). No statistically significant difference was observed between the two subgroups (P = 0.679) (Fig. 6B).

# Postoperative complications

We analyzed postoperative complications based on the timing of cataract extraction and IOL implantation, dividing the patients into three groups: pre-12 weeks, 12 weeks to 12 months, and post-12 months. Patients who underwent surgery before 12 weeks had significantly higher risks of VAO (31%) and glaucoma (26%), while those underwent surgery between 12 weeks and 12 months showed lower risks (VAO, 13%; glaucoma, 3%). Surgery after 12 months was associated with intermediate risks (VAO, 20%; glaucoma, 6%). Similar trends were observed for IOL implantation timing, with significantly higher risks of VAO (31%) and glaucoma (25%) before 12 weeks, lower risks between 12 weeks and 12 months (VAO, 12%; glaucoma, 3%), and intermediate risks after 12 months (VAO,15%; glaucoma, 6%). Significant differences were found among the glaucoma subgroups (P =0.001) but not among the VAO groups (P = 0.067) (Supplementary Fig. 2-5).

In the sensitivity analysis, omitting a single study at a time did not result in significant changes in the overall results. The Egger's test indicated no evidence of publication bias (Egger's P = 0.671) (Supplementary Fig. 1).

# Discussion

Our meta-analysis indicated that approximately 62% of children who underwent surgery for congenital cataracts developed amblyopia. The timing of cataract extraction is closely related to the prevalence of amblyopia, with earlier removal being associated with a lower prevalence. Conversely, the timing of IOL implantation appears to

<sup>(</sup>See figure on next page.)

**Fig. 5** Forest plot of the pooled proportion of amblyopia categorized by phenotype for the subgroups: **A** Unilateral complete occlusion, unilateral partial occlusion, bilateral complete occlusion, and bilateral partial occlusion; **B** Subgroup categorized by phenotype: Total, Nuclear, Posterior subcapsular, and other (including lamellar, anterior polar, punctate, and other opacities). Subgroup analyses are presented with effect sizes (proportions), 95% confidence intervals (CI), and heterogeneity metrics (I<sup>2</sup> statistic and *P*-value). CI = confidence interval; DL = DerSimonian-Laird random-effects model

A	Effect	
Study and Subgroup	(95% CI)	Weight(%)
Unilateral complete occlusion		
D. H. Kim 2012	0.32 (0.17, 0.47)	19.46
K. Rong 2015	0.49 (0.35, 0.63)	20.07
Ledoux, D. M. 2007	0.19 (0.04, 0.34)	18.86
Scott R. Lambert 2006	0.40 (0.10, 0.70)	8.26
Claude Speeg-Schatz 2005	0.44 (0.28, 0.60)	18.20
Erick D Bothun 2021	0.47 (0.28, 0.66)	15.14
Subgroup, DL (l² = 50.8%, p = 0.071)	0.38 (0.28, 0.48)	100.00
Unilateral partial occlusion		
D. H. Kim 2012	0.32 (0.17, 0.47)	18.39
X. Rong 2015	0.49 (0.31, 0.67)	15.50
Ledoux, D. M. 2007		23.69
Scott R. Lambert 2006	0.40 (0.23, 0.57)	15.54
Claude Speeg-Schatz 2005	0.44 (0.21, 0.67)	11.84
Erick D Bothun 2021	0.47 (0.21, 0.73)	11.67
Subgroup, DL (l <sup>2</sup> = 59.2%, p = 0.032)	0.36 (0.25, 0.47)	100.00
Bilateral complete occlusion		
(. Rong 2015	0.85 (0.68, 1.02)	24.20
(angzes, S. 2019	0.53 (0.41, 0.65)	26.08
-		28.08
edoux, D. M. 2007	0.47 (0.27, 0.67)	
Claude Speeg-Schatz 2005	0.89 (0.78, 1.00)	26.66
Subgroup, DL (l² = 89.2%, p = 0.000)	0.69 (0.47, 0.91)	100.00
Bilateral partial occlusion		
K. Rong 2015	0.85 (0.68, 1.02)	24.97
/angzes, S. 2019	0.53 (0.35, 0.71)	24.42
edoux, D. M. 2007	0.47 (0.32, 0.62)	25.65
Claude Speeg-Schatz 2005	0.89 (0.72, 1.06)	24.96
		100.00
Subgroup, DL (l² = 84.5%, p = 0.000)	0.68 (0.47, 0.90)	100.00
Heterogeneity between groups: p = 0.003		
Overall, DL (l² = 88.7%, p = 0.000)	0.50 (0.40, 0.61)	100.00
	Effect	
Study and Subgroup	(95% CI)	Weight (%
	(00/0 0/)	
Total		
D. H. Kim 2012	0.32 (0.17, 0.47	) 12.97
H. Zhang 2012	0.60 (0.49, 0.71	) 16.49
X. Rong 2015	0.60 (0.49, 0.71	) 16.30
Yangzes, S 2019	0.53 (0.41, 0.65	) 15.18
Ledoux, D. M 2007	0.32 (-0.14, 0.78	3) 2.67
Scott R. Lambert 2006	0.40 (0.12, 0.68	) 6.08
Claude Speeg-Schatz 2005	0.65 (0.54, 0.76	) 16.22
Mari Kathrine Sand 2022	0.65 (0.30, 1.00	) 4.15
Erick D Bothun 2022	0.47 (0.28, 0.66	9.93
Subgroup, DL (l <sup>2</sup> = 53.3%, p = 0.029)	0.53 (0.45, 0.61	) 100.00
Nuclear		
D. H. Kim 2012	0.32 (0.16, 0.48	) 18.60
H. Zhang 2012	0.60 (0.51, 0.69	
_edoux, D. M 2007	0.32 (0.16, 0.48	
Scott R. Lambert 2006	0.32 (0.18, 0.48	
Mari Kathrine Sand 2022	0.40 (0.22, 0.38	
Erick D Bothun 2021	0.85 (0.37; 0.93	,
Subgroup, DL (l <sup>2</sup> = 69.0%, p = 0.006)	0.47 (0.16, 0.78	
Posterior subcapsular	032/014.07	3) 8.55
D. H. Kim 2012	0.32 (-0.14, 0.72	
H. Zhang 2012	0.60 (0.49, 0.71	
Yangzes, S 2019	0.53 (0.18, 0.88 0.32 (0.18, 0.46	
Ledoux, D. M 2007 Mari Kathrine Sand 2022		
Mari Kathrine Sand 2022 Erick D Bothun 2021	0.65 (0.18, 1.12	
Enck D Bothun 2021 Subgroup, DL (l² = 53.7%, p = 0.056)	0.47 (0.03, 0.91	
	1	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Others		
1. Zhang 2012	0.60 (0.53, 0.67	
X. Rong 2015	0.60 (0.46, 0.74	
Yangzes, S 2019	0.53 (0.32, 0.74	
_edoux, D. M 2007	0.32 (0.20, 0.44	
Scott R. Lambert 2006	0.40 (-0.15, 0.9	
Claude Speeg-Schatz 2005	0.65 (0.48, 0.82	
Mari Kathrine Sand 2022	0.65 (0.18, 1.12	
Erick D Bothun 2021	0.47 (-0.02, 0.96	
Subgroup, DL (l² = 62.9%, p = 0.009)	0.53 (0.43, 0.64	) 100.00
Heterogeneity between groups: p = 0.704		
Heterogeneity between groups: $p = 0.704$ Dverall, DL ( $l^2 = 58.3\%$ , $p = 0.000$ )	0.51 (0.45, 0.56	) 100.00

Fig. 5 (See legend on previous page.)

Follow-up Duration	Effect (95% CI)	Weight(
> 8 years		
T. Yu, 2009	0.77 (0.54, 1.00)	3.29
A. Magli, 2015	0.79 (0.68, 0.90)	4.36
Adriano Magli, 2016	0.63 (0.54, 0.72)	4.52
H. H. Ye, 2007		3.96
S. R. Lambert, 2020	0.71 (0.59, 0.83)	4.28
Ledoux, D. M. 2001		4.58
Claude Speeg-Schatz 2005		4.49
Kenneth P. Cheng 1991	0.76 (0.56, 0.97)	3.55
Steven Awner 1996	0.67 (0.40, 0.93)	2.96
Subgroup, DL (I <sup>2</sup> = 88.8%, p = 0.000)	0.65 (0.52, 0.77)	36.00
4-8 years		
D. H. Kim, 2012	0.65 (0.49, 0.80)	3.99
X. Rong, 2015	0.60 (0.51, 0.69)	4.49
A. Be, 2022	0.88 (0.79, 0.97)	4.52
HUSSIN HM 2009	0.75 (0.62, 0.88)	4.16
E. Eugenie Hartmann 2014	0.48 (0.34, 0.62)	4.10
Mari Kathrine Sand 2022	0.65 (0.46, 0.84)	3.61
Rudolf Autrata 2005	0.61 (0.46, 0.76)	4.03
Erick D Bothun 2021	0.47 (0.32, 0.62)	3.98
Subgroup, DL ( $I^2 = 82.6\%$ , p = 0.000)	0.64 (0.53, 0.75)	32.90
< 4 years		
≤ 4 years		4.75
H. Zhang, 2012	0.66 (0.62, 0.70)	4.75
Yangzes, S. 2019	0.53 (0.43, 0.63)	4.43
Negalur, M. 2018	0.86 (0.75, 0.97)	4.36
Hennig, A. 2013	• 0.47 (0.42, 0.52)	4.73
J. Park, 2018	0.95 (0.88, 1.02)	4.63
Elie Dahan 1990	0.92 (0.78, 1.07)	4.07
Jean Jacques Aron 1983	0.93 (0.79, 1.06)	4.14
Subgroup, DL (I² = 96.4%, p = 0.000)	0.75 (0.60, 0.91)	31.10
Heterogeneity between groups: p = 0.444 Overall, DL (l² = 92.1%, p = 0.000)	0.68 (0.60, 0.75)	100.00
	0.68 (0.60, 0.75) Effect (95% Cl)	100.00 Weight
Overall, DL (l² = 92.1%, p = 0.000)		
Overall, DL (I² = 92.1%, p = 0.000) \ge at Last Follow-up • Age of 6 years	Effect (95% Cl)	
Overall, DL (I² = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years . Yu, 2009	Effect (95% Cl)	Weight 3.29
Overall, DL (l² = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years . Yu, 2009 . Magli, 2015	Effect (95% Cl)	Weight 3.29 4.36
Overall, DL (I² = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years . Yu, 2009 . Magli, 2015 9. H. Kim, 2012	Effect (95% Cl)	Weight 3.29 4.36 3.99
Overall, DL (I² = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years . Yu, 2009 . Magli, 2015 9. H. Kim, 2012	Effect (95% Cl)	Weight 3.29 4.36
Overall, DL (I <sup>2</sup> = 92.1%, p = 0.000) Age at Last Follow-up Age of 6 years . Yu, 2009 . Magli, 2015 D. H. Kim, 2012 I. Zhang, 2012	Effect (95% Cl)	Weight 3.29 4.36 3.99
Overall, DL (I <sup>2</sup> = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years . Yu, 2009 . Magli, 2015 . H. Kim, 2012 . Zhang, 2012 . Rong, 2015	Effect (95% Cl)	<b>Weight</b> 3.29 4.36 3.99 4.75 4.49
Overall, DL (I <sup>2</sup> = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years . Yu, 2009 . Magli, 2015 . H. Kim, 2012 . Zhang, 2012 . Rong, 2015 . Be, 2022	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52
Overall, DL (I <sup>2</sup> = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years Yu, 2009 . Magli, 2015 . H. Kim, 2012 . Zhang, 2012 . Rong, 2015 . Be, 2022 driano Magli, 2016	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52
Dverall, DL (I <sup>2</sup> = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years Yu, 2009 . Magli, 2015 . H. Kim, 2012 . Zhang, 2012 . Rong, 2015 . Be, 2022 driano Magli, 2016 USSIN HM 2009	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.52 4.16
Dverall, DL (I <sup>2</sup> = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years Yu, 2009 . Magli, 2015 . H. Kim, 2012 . Zhang, 2012 . Rong, 2015 . Be, 2022 driano Magli, 2016 USSIN HM 2009	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.52 4.16
Overall, DL (I <sup>2</sup> = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years . Yu, 2009 . Magli, 2015 . H. Kim, 2012 . Zhang, 2012 . Zhang, 2015 . Be, 2022 driano Magli, 2016 USSIN HM 2009 . H. Ye, 2007	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.52 4.16 3.96
Dverall, DL (I <sup>2</sup> = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years Yu, 2009 Magli, 2015 . H. Kim, 2012 . Zhang, 2012 . Rong, 2015 . Be, 2022 driano Magli, 2016 USSIN HM 2009 . H. Ye, 2007 . R. Lambert, 2020	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.52 4.56 4.28
Dverall, DL (I <sup>2</sup> = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years Yu, 2009 . Magli, 2015 . H. Kim, 2012 . Zhang, 2012 . Rong, 2015 . Be, 2022 driano Magli, 2016 USSIN HM 2009 . H. Ye, 2007 . R. Lambert, 2020 edoux, D. M. 2001	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.52 4.16 3.96 4.28 4.58
Dverall, DL (I <sup>2</sup> = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years Yu, 2009 . Magli, 2015 . H. Kim, 2012 . Zhang, 2012 . Zhang, 2012 . Bo, 2022 driano Magli, 2016 USSIN HM 2009 . H. Ye, 2007 . R. Lambert, 2020 edoux, D. M. 2001 laude Speeg-Schatz 2005	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.52 4.52 4.16 3.96 4.28 4.58 4.49
Dverall, DL (I <sup>2</sup> = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years .Yu, 2009 .Magli, 2015 .H. Kim, 2012 .Zhang, 2012 .Zhang, 2012 .Zhang, 2015 .Be, 2022 driano Magli, 2016 USSIN HM 2009 .H. Ye, 2007 .R. Lambert, 2020 edoux, D. M. 2001 laude Speeg-Schatz 2005 .Park, 2018	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.16 3.96 4.28 4.58 4.58 4.49 4.63
Dverall, DL (I <sup>2</sup> = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years .Yu, 2009 .Magli, 2015 .H. Kim, 2012 .Zhang, 2012 .Zhang, 2012 .Zhang, 2015 .Be, 2022 driano Magli, 2016 USSIN HM 2009 .H. Ye, 2007 .R. Lambert, 2020 edoux, D. M. 2001 laude Speeg-Schatz 2005 .Park, 2018	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.16 3.96 4.28 4.58 4.58 4.49 4.63
Dverall, DL (I <sup>2</sup> = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years Yu, 2009 Magli, 2015 . H. Kim, 2012 . Zhang, 2012 . Zhang, 2015 . Be, 2022 driano Magli, 2016 USSIN HM 2009 . H. Ye, 2007 . R. Lambert, 2020 edoux, D. M. 2001 laude Speeg-Schatz 2005 Park, 2018 enneth P. Cheng 1991	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.16 3.96 4.28 4.58 4.49 4.63 3.55
Dverall, DL (I² = 92.1%, p = 0.000)           ge at Last Follow-up           Age of 6 years           Yu, 2009           Magli, 2015           . H. Kim, 2012           . Zhang, 2012           . Rong, 2015           . Be, 2022           driano Magli, 2016           USSIN HM 2009           . H. Ye, 2007           . R. Lambert, 2020           adoux, D. M. 2001           laude Speeg-Schatz 2005           Park, 2018           enneth P. Cheng 1991           teven Awner 1996	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.16 3.96 4.28 4.58 4.49 4.63 3.55
Overall, DL (I² = 92.1%, p = 0.000)         age at Last Follow-up         Age of 6 years         . Yu, 2009         . Magli, 2015         . H. Kim, 2012         . Zhang, 2012         . Rong, 2015         . Be, 2022         . driano Magli, 2016         IUSSIN HM 2009         I. H. Ye, 2007         S. R. Lambert, 2020         edoux, D. M. 2001         claude Speeg-Schatz 2005         . Park, 2018         tevren Awner 1996         ubgroup, DL (I² = 91.9%, p = 0.000)	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.16 3.96 4.28 4.58 4.49 4.63 3.55 2.96
Overall, DL (I <sup>2</sup> = 92.1%, p = 0.000) Age of 6 years Yu, 2009 Magli, 2015 H. Kim, 2012 Zhang, 2015 Be, 2022 driano Magli, 2016 USSIN HM 2009 H. Ye, 2007 R. Lambert, 2020 edoux, D. M. 2001 Haubert, 2018 enneth P. Cheng 1991 teven Awner 1996 ubgroup, DL (I <sup>2</sup> = 91.9%, p = 0.000) <b>Age of 6 years</b>	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.16 3.96 4.28 4.58 4.58 4.49 4.63 3.55 2.96 62.55
Overall, DL (I <sup>2</sup> = 92.1%, p = 0.000)         ge at Last Follow-up         Age of 6 years         Yu, 2009         Magli, 2015         . H. Kim, 2012         . Zhang, 2012         . Rong, 2015         . Be, 2022         driano Magli, 2016         USSIN HM 2009         . H. Ye, 2007         . R. Lambert, 2020         edoux, D. M. 2001         laude Speeg-Schatz 2005         . Park, 2018         enneth P. Cheng 1991         teven Awner 1996         ubgroup, DL (I <sup>2</sup> = 91.9%, p = 0.000)         angzes, S. 2019	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.16 3.96 4.28 4.58 4.49 4.63 3.55 2.96 62.55
Overall, DL (I <sup>2</sup> = 92.1%, p = 0.000)         ge at Last Follow-up         Age of 6 years         . Yu, 2009         . Magli, 2015         . Kim, 2012         . Zhang, 2015         . Be, 2022         driano Magli, 2016         UUSSIN HM 2009         . H. Ye, 2007         . R. Lambert, 2020         edoux, D. M. 2001         !aude Speeg-Schatz 2005         . Park, 2018         ubgroup, DL (I <sup>2</sup> = 91.9%, p = 0.000) <b>age of 6 years</b> angzes, S. 2019         legalur, M. 2018	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.16 3.96 4.28 4.58 4.49 4.63 3.55 2.96 62.55 4.43 4.36
Overall, DL (I <sup>2</sup> = 92.1%, p = 0.000)         ge at Last Follow-up         Age of 6 years         Yu, 2009         Magli, 2015         H. Kim, 2012         Zhang, 2015         Be, 2022         driano Magli, 2016         USSIN HM 2009         H. Ye, 2007         R. Lambert, 2020         edoux, D. M. 2001         laude Speeg-Schatz 2005         . Park, 2018         enneth P. Cheng 1991         teven Awner 1996         ubgroup, DL (I <sup>2</sup> = 91.9%, p = 0.000) <b>Age of 6 years</b> angzes, S. 2019         egalur, M. 2018         . Eugenie Hartmann 2014	Effect (95% Cl) 0.77 (0.54, 1.00) 0.79 (0.68, 0.90) 0.65 (0.49, 0.80) 0.66 (0.62, 0.70) 0.60 (0.51, 0.69) 0.68 (0.79, 0.97) 0.63 (0.54, 0.72) 0.75 (0.62, 0.88) 0.58 (0.42, 0.74) 0.75 (0.62, 0.83) 0.58 (0.42, 0.74) 0.55 (0.42, 0.74) 0.65 (0.56, 0.74) 0.95 (0.88, 1.02) 0.76 (0.56, 0.97) 0.67 (0.40, 0.93) 0.69 (0.60, 0.78) 0.86 (0.75, 0.97) 0.48 (0.34, 0.62)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.16 3.96 4.28 4.58 4.49 4.63 3.55 2.96 62.55 4.43 4.36
Overall, DL (I <sup>2</sup> = 92.1%, p = 0.000)         ge at Last Follow-up         Age of 6 years         Yu, 2009         Magli, 2015         H. Kim, 2012         Zhang, 2015         Be, 2022         driano Magli, 2016         USSIN HM 2009         H. Ye, 2007         R. Lambert, 2020         edoux, D. M. 2001         laude Speeg-Schatz 2005         . Park, 2018         enneth P. Cheng 1991         teven Awner 1996         ubgroup, DL (I <sup>2</sup> = 91.9%, p = 0.000) <b>Age of 6 years</b> angzes, S. 2019         egalur, M. 2018         . Eugenie Hartmann 2014	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.16 3.96 4.28 4.58 4.49 4.63 3.55 2.96 62.55 4.43 4.36
Overall, DL (I <sup>2</sup> = 92.1%, p = 0.000)         ge at Last Follow-up         Age of 6 years         . Yu, 2009         . Magli, 2015         . H. Kim, 2012         . Zhang, 2015         . Bay, 2015         . Bong, 2015         . Be, 2022         driano Magli, 2016         USSIN HM 2009         . H. Ye, 2007         . R. Lambert, 2020         edoux, D. M. 2001         laude Speeg-Schatz 2005         . Park, 2018         enneth P. Cheng 1991         teven Awner 1996         ubgroup, DL (I <sup>2</sup> = 91.9%, p = 0.000) <b>: Age of 6 years</b> angzes, S. 2019         egalur, M. 2018         Eugenie Hartmann 2014         tari Kathrine Sand 2022	Effect (95% Cl) 0.77 (0.54, 1.00) 0.79 (0.68, 0.90) 0.65 (0.49, 0.80) 0.66 (0.62, 0.70) 0.60 (0.51, 0.69) 0.68 (0.79, 0.97) 0.63 (0.54, 0.72) 0.63 (0.54, 0.72) 0.75 (0.62, 0.88) 0.58 (0.42, 0.74) 0.71 (0.59, 0.83) 0.32 (0.24, 0.40) 0.65 (0.56, 0.74) 0.95 (0.88, 1.02) 0.76 (0.56, 0.97) 0.67 (0.40, 0.93) 0.69 (0.60, 0.78) 0.53 (0.43, 0.63) 0.68 (0.75, 0.97) 0.48 (0.34, 0.62) 0.65 (0.46, 0.84)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.52 4.16 3.96 4.28 4.58 4.49 4.63 3.55 2.96 62.55 4.43 4.36 4.36 4.10 3.61
Overall, DL (I <sup>2</sup> = 92.1%, p = 0.000)           Age of 6 years           . Yu, 2009           . Magli, 2015           . H. Kim, 2012           . Zhang, 2015           . Be, 2022           driano Magli, 2016           IUSSIN HM 2009           . H. Ye, 2007           . R. Lambert, 2020           edoux, D. M. 2001           daude Speeg-Schatz 2005           . Park, 2018           enneth P. Cheng 1991           teven Awner 1996           ubgroup, DL (I <sup>2</sup> = 91.9%, p = 0.000) <b>age of 6 years</b> angzes, S. 2019           legalur, M. 2018           . Eugenie Hartmann 2014           Lair Kathrine Sand 2022           uodolf Autrata 2005	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.16 3.96 4.28 4.58 4.49 4.63 3.55 2.96 62.55 4.43 4.36 4.10 3.61 4.03
Overall, DL ( $l^2$ = 92.1%, p = 0.000)         age at Last Follow-up         Age of 6 years         . Yu, 2009         . Magli, 2015         . H. Kim, 2012         . Zhang, 2012         . Rong, 2015         . Be, 2022         driano Magli, 2016         IUSSIN HM 2009         . H. Ye, 2007         . R. Lambert, 2020         edoux, D. M. 2001         daude Speeg-Schatz 2005         . Park, 2018         enneth P. Cheng 1991         teven Awner 1996         ubgroup, DL ( $l^2$ = 91.9%, p = 0.000)         agges, S. 2019         legalur, M. 2018         . Eugenie Hartmann 2014         tari Kathrine Sand 2022         udolf Autrata 2005         lennig, A. 2013	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.16 3.96 4.28 4.49 4.63 3.55 2.96 62.55 4.43 4.36 4.10 3.61 4.03 4.73
Overall, DL ( $l^2$ = 92.1%, p = 0.000)         gg at Last Follow-up         Age of 6 years         . Yu, 2009         . Magli, 2015         . Kim, 2012         . Zhang, 2015         . Be, 2022         driano Magli, 2016         UUSSIN HM 2009         . H. Ye, 2007         . R. Lambert, 2020         edoux, D. M. 2001         !aude Speeg-Schatz 2005         . Park, 2018         enneth P. Cheng 1991         teven Awner 1996         ubgroup, DL ( $l^2$ = 91.9%, p = 0.000) <b>age of 6 years</b> angzes, S. 2019         legalur, M. 2018         . Eugenie Hartmann 2014         lari Kathrine Sand 2022         udolf Autrata 2005         iudolf Autrata 2005	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.16 3.96 4.28 4.58 4.49 4.63 3.55 2.96 62.55 4.43 4.36 4.10 3.61 4.03 3.51 5.296 62.55
Overall, DL ( $l^2$ = 92.1%, p = 0.000)         gg at Last Follow-up         Age of 6 years         . Yu, 2009         . Magli, 2015         . Kim, 2012         . Zhang, 2015         . Be, 2022         driano Magli, 2016         UUSSIN HM 2009         . H. Ye, 2007         . R. Lambert, 2020         edoux, D. M. 2001         !aude Speeg-Schatz 2005         . Park, 2018         enneth P. Cheng 1991         teven Awner 1996         ubgroup, DL ( $l^2$ = 91.9%, p = 0.000) <b>age of 6 years</b> angzes, S. 2019         legalur, M. 2018         . Eugenie Hartmann 2014         lari Kathrine Sand 2022         udolf Autrata 2005         iudolf Autrata 2005	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.16 3.96 4.28 4.58 4.49 4.63 3.55 2.96 62.55 4.43 4.36 4.10 3.61 4.03 3.51 5.296 62.55
Dverall, DL ( $l^2$ = 92.1%, p = 0.000) ge at Last Follow-up Age of 6 years . Yu, 2009 . Magli, 2015 . H. Kim, 2012 . Zhang, 2012 . Rong, 2015 . Be, 2022 driano Magli, 2016 USSIN HM 2009 . H. Ye, 2007 . R. Lambert, 2020 edoux, D. M. 2001 laude Speeg-Schatz 2005 . Park, 2018 enneth P. Cheng 1991 teven Awner 1996 ubgroup, DL ( $l^2$ = 91.9%, p = 0.000) <b>: Age of 6 years</b> angzes, S. 2019 egalur, M. 2018 . Eugenie Hartmann 2014 lari Kathrine Sand 2022 udolf Autrata 2005 ennig, A. 2013 rick D Bothun 2021 lie Dahan 1990	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.52 4.52 4.58 4.28 4.28 4.43 3.55 2.96 62.55 4.43 4.36 4.10 3.61 4.03 3.98 4.07
Overall, DL ( $l^2$ = 92.1%, p = 0.000)         age at Last Follow-up         Age of 6 years         . Yu, 2009         . Magli, 2015         . H. Kim, 2012         . Zhang, 2015         . Bong, 2015         . Be, 2022         driano Magli, 2016         UUSSIN HM 2009         . H. Ye, 2007         . R. Lambert, 2020         edoux, D. M. 2001         daude Speeg-Schatz 2005         . Park, 2018         enneth P. Cheng 1991         teven Awner 1996         ubgroup, DL ( $l^2$ = 91.9%, p = 0.000) <b>age of 6 years</b> angzes, S. 2019         legalur, M. 2018         . Eugenie Hartmann 2014         tari Kathrine Sand 2022         udolf Autrata 2005         lennig, A. 2013         rick D Bothun 2021         lie Dahan 1990         ean Jacques Aron 1983	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.52 4.52 4.58 4.28 4.58 4.49 4.63 3.55 2.96 62.55 4.43 4.36 4.10 3.61 4.03 3.73 3.98 4.07
Overall, DL ( $l^2$ = 92.1%, p = 0.000) age at Last Follow-up Age of 6 years . Yu, 2009 . Magli, 2015 . H. Kim, 2012 . Rong, 2015 . Be, 2022 . Rong, 2015 . Be, 2022 . Rong, 2015 . Be, 2022 . Kordin Magli, 2016 . USSIN HM 2009 . H. Ye, 2007 3. R. Lambert, 2020 edoux, D. M. 2001 . Have a speeg-Schatz 2005 . Park, 2018 . Genneth P. Cheng 1991 . Evern Awner 1996 . Bubgroup, DL ( $l^2$ = 91.9%, p = 0.000) <b>a Age of 6 years</b> . Tangzes, S. 2019 legalur, M. 2018 . Eugenie Hartmann 2014 . Mari Kathrine Sand 2022 tudolf Autrata 2005 . Jennig, A. 2013 . Frick D Bothun 2021 . Software a speeger of the state of the sta	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.16 3.96 4.28 4.58 4.49 4.63 3.55 2.96 62.55 4.43 4.36 4.10 3.61 4.03 4.73 3.98 4.75 2.96 62.55
Overall, DL (I² = 92.1%, p = 0.000) Age at Last Follow-up	Effect (95% Cl)	Weight 3.29 4.36 3.99 4.75 4.49 4.52 4.52 4.16 3.96 4.28 4.58 4.49 4.63 3.55 2.96 62.55 4.43 4.36 4.10 3.61 4.03 4.73 3.98 4.75 2.96 62.55

**Fig. 6** Forest plots of the pooled prevalence of amblyopia stratified by: **A** Follow-up duration ( $\leq$  4 years, 4–8 years, > 8 years post-surgery); **B** Age at last follow-up ( $\leq$  6 years vs. > 6 years). Subgroup analyses are presented with effect sizes (proportions), 95% confidence intervals (CI), and heterogeneity metrics ( $I^2$  statistic and *P*-value). CI = confidence interval; DL = DerSimonian-Laird random-effects model

have a minor impact on postoperative visual outcomes. Regardless of whether lens removal or IOL implantation is performed earlier, patients face significant risks of complications, such as glaucoma and VAO. Additionally, our study found that patients with complete obstruction in both eyes exhibited better visual recovery than those with partial obstruction in a single eye (P= 0.01). Interestingly, beyond 6 years of age, an extended follow-up period did not result in a significant visual recovery. We discuss these findings in greater detail below.

Our findings underscore the importance of early diagnosis and intervention to reduce the incidence of amblyopia. Data show that the prevalence of amblyopia in patients with unilateral cataract decreases from 79% when surgery is performed after 12 months to 53% when conducted before 8 weeks, and from 72% to 39% in patients with bilateral cataract. These findings align with Birch and Stager's study, which demonstrated that surgery before 6 weeks of age significantly improves visual prognosis in patients with unilateral cataracts [46]. This 6-week threshold, known as the latent period, relies on subcortical pathways in the developing visual system to prevent form deprivationinduced vision loss [47, 48]. Emerging evidence suggests that this critical window is modulated by broader neuro developmental processes. For instance, infants with congenital cataracts may exhibit delayed myelination of the optic radiations, as observed in diffusion tensor imaging studies [49], which could further constrain the time frame for effective visual rehabilitation. Additionally, crossmodal plasticity where auditory or somatosensory cortices encroach on visually deprived area may compete with residual visual plasticity, potentially explaining why delayed intervention beyond the latent period yields diminished gains [50]. Additionally, research suggests that the latent period for bilateral visual deprivation may extend for up to 10 weeks [7]. These data emphasize the importance of performing surgery within the latent period to maximize the development of visual function and further elucidate the critical role of the latent period in visual recovery.

Our results show that the timing of IOL implantation, whether in the primary or secondary phase, or within the first 12 weeks or after 12 months of life, does not significantly affect the prevalence of amblyopia in patients. This might be attributed to the fact that almost all patients received proper visual correction after cataract removal, such as wearing spectacles or contact lenses while in an aphakic status. However, earlier intervention ( $\leq 12$  weeks) was associated with higher complication rates with VAO (52% in the  $\leq 12$ -week group vs. 47% in the > 12-month group (p = 0.32)) and Glaucoma (26% vs. 6% (p = 0.004)). Our findings indicates that the occurrence of VAO tends to be higher with earlier surgical intervention; however, no significant correlation was observed in

the subgroup analysis based on timing, consistent with Negalur's observations that VAO development is not linked to age at the time of surgery [15]. Nevertheless, a substantial increase in the prevalence of glaucoma warrants further attention. A recently published meta-analysis on the correlation between congenital cataract surgery and the incidence of secondary glaucoma indicated that the average age at surgery was an independent factor influencing the development of secondary glaucoma [51]. Birch and Cheng also found that surgery within the first 4 weeks of life led to a higher occurrence of glaucoma [52]. An examination of 147 eyes with congenital cataracts in Victoria, Australia, revealed that the prevalence of glaucoma was the highest in surgeries performed within the first month of life [53]. The risk of glaucoma decreases as the age at the time of surgery increased [54, 55].

Combining the conclusions drawn from cataract extraction, we believe that early removal of opacified lenses is crucial for postoperative vision recovery and the prevention of amblyopia. While ensuring that patients receive appropriate visual correction and rehabilitation, delaying the timing of IOL implantation could strike a balance between maximizing visual recovery and minimizing the risk of serious complications, such as glaucoma.

Our results showed clear differences in visual outcomes with respect to the various cataract phenotypes. The prevalence of amblyopia was significantly higher in unilateral complete and partial obstruction cataracts (69% and 68%, respectively) than in bilateral cataracts (38% and 36%, respectively). This result is understandable, as unilateral congenital cataract leads to early monocular deprivation, adversely affecting visual outcomes compared with deprivation in both eyes [47]. Studies on monocularly deprived animals have shown that the columnar regions of the deprived eye in layer 4c of the primary visual cortex are almost three times narrower than those of the non-deprived eyes [47, 56]. In humans, functional MRI studies corroborate these findings, demonstrating reduced blood-oxygen-leveldependent (BOLD) signals in the primary visual cortex of children with untreated congenital cataracts [57]. These structural and functional alterations highlight the critical role of early surgical intervention in preserving cortical organization, as delayed treatment may lead to irreversible neural remodeling. Lambert et al. showed that bilateral visual deprivation during early childhood has a less severe impact on visual system development than unilateral deprivation [58]. In our study, relatively poorer postoperative visual acuity was observed in monocularly deprived unilateral congenital cataracts than in bilateral congenital cataracts (P = 0.01). When both eyes were deprived, the damage was less severe, indicating that the impairment was not solely due to lack of use, but also

due to competition between the two eyes. Therefore, the prognosis for patients with unilateral congenital cataracts is generally regarded as less favorable, and visual acuity is higher in patients with bilateral congenital cataracts even in cases of complete obstruction. This can assist clinical ophthalmologists in predicting the prognosis of patients before surgery while raising awareness for children with unilateral cataracts encountered in clinical practice.

We also categorized the patients into four groups based on the following cataract phenotypes: total, nuclear, posterior subcapsular, and other cataracts (including lamellar, anterior polar, punctate, and other opacities). Unlike previous classifications, the detailed classification of cataracts did not significantly affect postoperative visual outcomes. In fact, in the reviewed studies, a detailed description of the diagnostic process was often lacking. We believe that the limited availability of studies investigating the correlation between cataract phenotypes and postoperative visual outcomes might explain the lack of a significant effect.

Another important finding of our study is that the recovery of vision tends to plateau after a certain period. Specifically the prevalence rate of amblyopia was 75% with a follow-up duration of 4 years postoperatively. Extending the follow-up period to 4-8 years resulted in a prevalence rate of 64%. We found that the prevalence rate decreased significantly from 75 to 64%, indicating that prolonged follow-up contributes to a reduction in the prevalence of amblyopia. However, when comparing the follow-up periods of 4–8 years and  $\geq 8$  years, the decrease in amblyopia rates was minimal, suggesting a relatively short golden period for visually deprived amblyopia caused by congenital cataracts. When exploring the relationship between the last follow-up age and amblyopia, using 6 years as the dividing point, we found no significant difference between the two groups. This finding indirectly confirms that, beyond 6 years of age, prolonged follow-up may not significantly contribute to visual recovery. The sensitive period is the timeframe during which the developing visual system retains plasticity and can be manipulated, influenced, or modified before full visual maturation [56, 59]. Suwal et al. indicated that for patients with amblyopia caused by ptosis and refractive error, proactive amblyopia treatment can significantly improve vision even at the age of 16 [60]. Studies have reported that for non-visually deprived amblyopia patients, significant improvements in vision can be achieved through active amblyopia training even at older ages [61, 62]. When categorizing follow-up timing, we attempted several subgroup analyses within smaller age groups. However, due to the limited availability of useful data for patients younger than 6 years in the literature, we could only observe differences in percentages without significant intergroup distinctions. Based on our conclusions, we believe that amblyopia caused by congenital cataracts has a shorter postoperative recovery time than the other types of amblyopia. Therefore, if we can effectively harness this period of visual plasticity for amblyopia training, it has the potential to maximize visual recovery in patients.

We acknowledge the limitations of this study. First, we categorized the timing of unilateral surgery as before eight weeks. However, previous studies suggest that the optimal timing for unilateral surgery is within the first 4-6 weeks of life [46]. The discrepancy in our categorization stems from the limited availability of studies that provided data for early intervention. This highlights a potential gap in the literature, emphasizing the need for further research on the earliest possible intervention times to optimize the visual outcomes in children with congenital cataracts. Second, our exclusion criteria intentionally omitted congenital cataracts associated with genetic syndromes [63, 64] or prenatal infections [65]. While this approach enhanced the homogeneity of our cohort, it limits the generalizability of findings to syndromic cataracts, where amblyopia risk may be compounded by additional ocular or systemic anomalies [66]. Future studies should address phenotype-specific outcomes in these populations. Although preventive measures are critical in reducing congenital cataract incidence, our analysis focused on postoperative outcomes rather than etiology. The interplay between prevention strategies and surgical timing warrants dedicated investigation. Third, our data predominantly represent small populations and thus may not offer a comprehensive representation of the entire population. Fourth, these data were extracted from several studies, making it difficult to unify surgical procedures, IOL types, and the process of amblyopia training. Finally, there might be language bias because our study included only studies published in English.

### Conclusion

Our study demonstrates that early surgical intervention ( $\leq 8$  weeks for unilateral,  $\leq 12$  weeks for bilateral congenital cataracts) significantly reduces amblyopia prevalence, although it comes with an increased risk of postoperative complications. Notably, IOL implantation timing showed no clinically meaningful impact on visual outcomes, challenging the rationale for early IOL placement in infants. Additionally, our findings indicate that the cataract phenotype critically influences prognosis, emphasizing the urgency of prioritizing unilateral cataract management. Furthermore, the therapeutic window for amblyopia rehabilitation is constrained, with limited efficacy observed beyond 6 years of age, emphasizing the need for age-targeted interventions during the critical period of visual plasticity.

### Abbreviations

BCVA	Best-corrected visual acuity
BOLD	Blood-oxygen-level-dependent
IOL	Intraocular lens
NOS	Newcastle–Ottawa Scale
PHPV/PFV	Persistent hyperplastic primary vitreous / Persistent fetal vasculature
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
RCT	Randomized controlled trial
VAO	Visual axis opacification

# **Supplementary Information**

The online version contains supplementary material available at https://doi. org/10.1186/s13052-025-02010-x.

Supplementary Material 1.

### Acknowledgements

The authors thank all the children and families involved in the original studies included in this meta-analysis.

### Authors' contributions

STXC and AH conceived and designed the study. AH conducted the literature search, data extraction, and preliminary analysis. YXN and AH drafted the initial manuscript and performed statistical analysis. STXC, YXN, and AH revised and edited the manuscript. YK and STXC supervised the study and ensured quality control.

### Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 82371037, 82171033) and the National Key Research and Development Program of China (Grant No. 2024YFC2510900/2024YFC2510904).

### Data availability

All data generated or analyzed during this study are included in this published article and its supplementary information files.

### Declarations

### Ethics approval and consent to participate

This study was based on previously conducted studies and did not involve any new experiments with human participants or animals performed by the authors.

### **Consent for publication**

Not applicable.

### **Competing interests**

The authors declare that they have no competing interests.

Received: 28 November 2024 Accepted: 11 May 2025 Published online: 19 May 2025

### References

- 1. Solebo AL, Teoh L, Rahi J. Epidemiology of blindness in children. J Arch Dis Child. 2017;102(9):853–7.
- Pi LH, Chen L, Liu Q, Ke N, Fang J, Zhang S, et al. Prevalence of eye diseases and causes of visual impairment in school-aged children in Western China. J Epidemiol. 2012;22(1):37–44.
- 3. Wong AM. Amblyopia (lazy eye) in children. CMAJ. 2014;186(4):292.
- Yu T, Dahan E. Bilateral uneven cataracts in children: amblyopia management by sequential intraocular lens implantation. J Eye (Lond). 2009;23(6):1451–5.

- Khokhar S, Pillay G, Agarwal E. Pediatric cataract—importance of early detection and management. Indian J Pediatr. 2018:209–216. https://doi. org/10.1007/s12098-017-2482-2.
- Kim DH, Kim JH, Kim SJ, Yu YS. Long-term results of bilateral congenital cataract treated with early cataract surgery, aphakic glasses and secondary IOL implantation. J Acta Ophthalmol. 2012;90(3):231–6.
- Lambert SR, Lynn MJ, Reeves R, et al. Is there a latent period for the surgical treatment of children with dense bilateral congenital cataracts? J AAPOS. 2006;10:30–6. https://doi.org/10.1016/j.jaapos.2005.10.002.
- Zhang Z, Fu Y, Wang J, Ji X, Li Z, Zhao Y, Chang P, Zhao YE. Glaucoma and risk factors three years after congenital cataract surgery. J BMC Ophthalmol. 2022;22(1):118.
- Trivedi RH, Wilson ME Jr, Golub RL. Incidence and risk factors for glaucoma after pediatric cataract surgery with and without intraocular lens implantation. J AAPOS. 2006;10(2):117–23.
- Sukhija J, Ram J, Gupta N, Sawhney A, Kaur S. Long-term results after primary intraocular lens implantation in children operated less than 2 years of age for congenital cataract. Indian J Ophthalmol. 2014;62(12):1132–5.
- Solebo AL, Rahi JS, British Congenital Cataract Interest G. Glaucoma following cataract surgery in the first 2 years of life: frequency, risk factors and outcomes from iol under 2. Br J Ophthalmol. 2020;104(7):967–73.
- Bronsard A, Geneau R, Shirima S, Courtright P, Mwende J. Why are children brought late for cataract surgery? Qualitative findings from Tanzania. J Ophthalmic Epidemiol. 2008;15(6):383–8.
- Asrani S, Freedman S, Hasselblad V, et al. Does primary intraocular lens implantation prevent'aphakic' glaucoma in children. J AAPOS. 2000;4:33–9.
- Kaplan AT, Yalçın SÖ, Oral AY. Primary versus secondary intraocular lens implantation following removal of congenital/developmental cataracts: outcomes after at least 4 years. J Turk J Med Sci. 2023;53(1):77–87.
- Negalur M, Sachdeva V, Neriyanuri S, Ali MH, Kekunnaya R. Long-term outcomes following primary intraocular lens implantation in infants younger than 6 months. J Indian J Ophthalmol. 2018;66(8):1088–93.
- Yorston D. Intraocular Lens (IOL) implants in children. J Community Eye Health. 2001;14(40):57–8.
- 17. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Ann Intern Med. 2009;151(4):264–9. W64.
- 18. Stroup DF, Berlin JA, Morton SC. Meta-analysis of observa-tional studies in epidemiology: a proposal for reporting. J JAMA. 2000;283:2008–12.
- Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. J Eur J Epidemiol. 2010;25(9):603–5.
- Chinese Association for Pediatric Ophthalmology and Strabismus; Pediatric Ophthalmology and Strabismus Group of Chinese Ophthalmologist Association. Expert consensus on prevention and treatment of amblyopia in children. Zhonghua Yan Ke Za Zhi. 2021;57(5):336–40. Chinese.
- Hutchinson AK, Morse CL. Pediatric eye evaluations preferred practice pattern [Practice guideline]. Ophthalmology. 2023;130(3):P222–70.
- Lambert SR, Cotsonis G, DuBois L, NizamMs A, Kruger SJ, Hartmann EE, et al. Long-term effect of intraocular lens vs contact lens correction on visual acuity after cataract surgery during infancy: a randomized clinical trial. JAMA Ophthalmol. 2020;138(4):365–72.
- Magli A, Forte R, Carelli R, Magli G, Esposito F, Torre A. Long-term followup after surgery for congenital and developmental cataracts. Semin Ophthalmol. 2016;31(3):261–5.3.
- Ye HH, Deng DM, Qian YY, Lin Z, Chen WR. Long-term visual outcome of dense bilateral congenital cataract. Chin Med J (Engl). 2007;120(17):1494–7.
- Magli A, Forte R, Carelli R, Rombetto L, Magli G. Long-term outcomes of primary intraocular lens implantation for unilateral congenital cataract. Semin Ophthalmol. 2016;31(6):548–53.
- Zhang H, Xie L, Wu X, Tian J. Long-term results of pediatric cataract surgery after delayed diagnosis. J AAPOS. 2012;16(1):65–9.
- Rong X, Ji Y, Fang Y, Jiang Y, Lu Y. Long-term visual outcomes of secondary intraocular lens implantation in children with congenital cataracts. PLoS ONE. 2015;10(7): e0134864.
- 28. Park J, Lee YG, Kim KY, Kim BY. Predicting factor of visual outcome in unilateral idiopathic cataract surgery in patients aged 3 to 10 years. Korean J Ophthalmol. 2018;32(4):273–80.

- Beheshtnejad A, Hashemian H, Kakaie S, Mahdavi A, Naderan M. Outcomes of the infantile cataract surgery: case series with a 5-year follow-up. Int Ophthalmol. 2022;42(2):541–7.
- Brown SM, Archer S, Del Monte MA. Stereopsis and binocular vision after surgery for unilateral infantile cataract. J AAPOS. 1999;3(2):109–13.
- Gochnauer AC, Trivedi RH, Hill EG, Wilson ME. Interocular axial length difference as a predictor of postoperative visual acuity after unilateral pediatric cataract extraction with primary IOL implantation. J AAPOS. 2010;14(1):20–4.
- 32. Yangzes S, Kaur S, Gupta PC, Sharma M, Jinagal J, Singh J, et al. Intraocular lens implantation in children with unilateral congenital cataract in the first 4 years of life. Eur J Ophthalmol. 2019;29(3):304–8.
- Ledoux DM, Trivedi RH, Wilson ME Jr, Payne JF. Pediatric cataract extraction with intraocular lens implantation: visual acuity outcome when measured at age four years and older. JAAPOS. 2007;11(3):218–24.
- Hartmann EE, Lynn MJ, Lambert SR, Infant Aphakia Treatment Study G. Baseline characteristics of the infant aphakia treatment study population: predicting recognition acuity at 4.5years of age. Invest Ophthalmol Vis Sci. 2014;56(1):388–95.
- Wackerberg D, Nystrom A, Haargaard B, Rosensvard A, Tornqvist K, Borg L, et al. Analysis of age at detection and outcomes of dense unilateral congenital cataract surgery for children on the paediatric cataract register. Acta Paediatr. 2023;112(2):277–85.
- Speeg-Schatz C, Flament J, Weissrock M. Congenital cataract extraction with primary aphakia and secondary intraocular lens implantation in the ciliary sulcus. J Cataract Refract Surg. 2005;31(4):750–6.
- 37. Autrata R, Rehurek J, Vodickova K. Visual results after primary intraocular lens implantation or contact lens correction for aphakia in the first year of age. Ophthalmologica. 2005;219(2):72–9.
- Dahan E, Salmenson BD. Pseudophakia in children: precautions, technique, and feasibility. J Cataract Refract Surg. 1990;16(1):75–82.
- Awner S, Buckley EG, DeVaro JM, Seaber JH. Unilateral pseudophakia in children under 4 years. J Pediatr Ophthalmol Strabismus. 1996;33(4):230–6.
- Cheng KP, Hiles DA, Biglan AW, Pettapiece MC. Visual results after early surgical treatment of unilateral congenital cataracts. Ophthalmology. 1991;98(6):903–10.
- Aron JJ, Aron-Rosa D. Intraocular lens implantation in unilateral congenital cataract: a preliminary report. J Am Intraocul Implant Soc. 1983;9(3):306–8 Summer.
- 42. Bothun ED, Wilson ME, Yen KG, Anderson JS, Weil NC, Loh AR, Morrison D, Freedman SF, Plager DA, Vanderveen DK, Traboulsi El, Hodge DO, Lambert SR; Toddler Aphakia and Pseudophakia Study. Outcomes of bilateral cataract surgery in infants 7 to 24 months of age using the toddler aphakia and pseudophakia treatment study registry. Ophthalmology. 2021;128(2):302–308.
- Hussin HM, Markham R. Long-term visual function outcomes of congenital cataract surgery with intraocular lens implantation in children under 5 years of age. Eur J Ophthalmol. 2009;19(5):754–61.
- Hennig A, Schroeder B, Gilbert C. Bilateral pediatric cataract surgery: outcomes of 390 children from Nepal and Northern India. J Pediatr Ophthalmol Strabismus. 2013;50(5):312–9.5.
- Sand MK, Cholidis S, Kristianslund O, Drolsum L. Primary intraocular lens implantation in infants with unilateral congenital cataract operated before 12 weeks of age. Acta Ophthalmol. 2022;100(5):526–33.
- Birch EE, Stager DR. The critical period for surgical treatment of dense congenital unilateral cataract. J Invest Ophthalmol Vis Sci. 1996;37(8):1532–8.
- Lewis TL, Maurer D. Multiple sensitive periods in human visual development: evidence from visually deprived children. J Dev Psychobiol. 2005;46:163–83.
- Chen S, Liu X, Sha X, Yang X, Yu X. Relationship between axial length and spherical equivalent refraction in Chinese children. J Adv Ophthalmol Pract Res. 2021;1(2): 100010.
- Benders MJ, Palmu K, Menache C, Borradori-Tolsa C, Lazeyras F, Sizonenko S, Dubois J, Vanhatalo S, Hüppi PS. Early brain activity relates to subsequent brain growth in premature infants. Cereb Cortex. 2015;25(9):3014–24.
- 50. Bavelier D, Dye MW, Hauser PC. Do deaf individuals see better? Trends Cogn Sci. 2006;10(11):512–8.

- Li L, Wang X, Liu C, Wang S, Wang X. Incidence rate of secondary glaucoma following congenital cataract surgery: an in-depth systematic review and meta-analysis. J Am J Ophthalmol. 2024;26(265):176–88.
- 52. Birch EE, Cheng C, Stager DR Jr, Weakley DR Jr, Stager DR Sr. The critical period for surgical treatment of dense congenital bilateral cataracts. J AAPOS. 2009;13(1):67–71.
- Ruddle JB, Staffieri SE, Crowston JG, Sherwin JC, Mackey DA. Incidence and predictors of glaucoma following surgery for congenital cataract in the first year of life in Victoria. Australia J Clin Exp Ophthalmol. 2013;41(7):653–61.
- Wang S, Repka MX, Sutherland DR, Hatt SR, Traboulsi EI, Lambert SR, Melia BM, Kraker RT, Holmes JM, Cotter SA; Pediatric Eye Disease Investigator Group. Complications, visual acuity, and refractive error 3 years after secondary intraocular lens implantation for pediatric aphakia. Ophthalmology. 2024;131(10):1196–1206.
- Haargaard B, Ritz C, Oudin A, Wohlfahrt J, Thygesen J, Olsen T, et al. Risk of glaucoma after pediatric cataract surgery. J Invest Ophthalmol Visual Sci. 2008;49:1791–6.
- Bremond-Gignac D, Copin H, Lapillonne A, Milazzo S, European Network of S, Research in Eye D. Visual development in infants: physiological and pathological mechanisms. J Curr Opin Ophthalmol. 2011;22 Suppl:S1–8.
- Nelson W, Mayhew SD. Investigating the consistency of negative BOLD responses to combinations of visual, auditory, and somatosensory stimuli and their modulation by the level of task demand. Hum Brain Mapp. 2025;46(4):e70177.
- Lambert SR, Lynn MJ, Hartmann EE, DuBois L, Drews-Botsch C, et al. Comparison of contact lens and intraocular lens correction of monocular aphakia during infancy: a randomized clinical trial of HOTV optotype acuity at age 4.5 years and clinical findings at age 5 years. JAMA Ophthalmol. 2014;132(6):676–82.
- 59. Solebo AL, Cumberland P, Rahi JS, British Isles Congenital Cataract Interest G. 5-year outcomes after primary intraocular lens implantation in children aged 2 years or younger with congenital or infantile cataract: findings from the IoLunder2 prospective inception cohort study. Lancet Child Adolesc Health. 2018;2(12):863–71.
- Suwal R, Dev MK, Khatri B, Khadka D, Shrestha A, Sharma S, Upadhyay MP. Impact of active vision therapy compared to conventional patching therapy on visual acuity and stereoacuity in children with amblyopia. J Optom. 2024;17(1):100484.
- 61. Dubowitz LM, Mushin J, De Vries L, GB Arden. Visual function in the newborn infant: is it cortically mediated? Lancet. 1986;1:1139–41.
- 62. Zhu Q, Zhao Q, Liang R, et al. Effectiveness of binocular therapy as a complementary treatment of part-time patching in older amblyopic children: a randomized clinical trial. Int Ophthalmol. 2023;43:2433–45.
- 63. Piccione M, Serra G, Sanfilippo C, Andreucci E, Sani I, Corsello G. A new mutation in EDA gene in X-linked hypohidrotic ectodermal dysplasia associated with keratoconus. Minerva Pediatr. 2012;64(1):59–64.
- Serra G, Antona V, Cannata C, Giuffrè M, Piro E, Schierz IAM, Corsello G. Distal Arthrogryposis type 5 in an Italian family due to an autosomal dominant gain-of-function mutation of the PIEZO2 gene. Ital J Pediatr. 2022;48(1):133.
- 65. Serra G, Carta M, Di Pace MR, La Sala E, Piro E, Salerno S, Schierz IAM, Vassallo A, Giuffrè M, Corsello G. Congenital syphilis in a preterm newborn with gastrointestinal disorders and postnatal growth restriction. Ital J Pediatr. 2022;48(1):205.
- 66. Serra G, Giambrone C, Antona V, Cardella F, Carta M, Cimador M, Corsello G, Giuffrè M, Insinga V, Maggio MC, Pensabene M, Schierz IAM, Piro E. Congenital hypopituitarism and multiple midline defects in a newborn with non-familial Cat Eye syndrome. Ital J Pediatr. 2022;48(1):170.

# **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.